{"content":"<li class=\"n-box-item date-title\" data-end=\"1485925199\" data-start=\"1485838800\" data-txt=\"Sunday, December 22, 2019\">Tuesday, January 31, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3239348\" data-ts=\"1485911803\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTCH\" target=\"_blank\">MTCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239348-match-groupminus-5_6-q1-fy-2017-revenue-forecasts-below-expectations-princeton-review\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Match Group -5.6%; Q1, FY 2017 revenue forecasts below expectations, The Princeton Review divested [updated]</a></h4><ul><li><strong><a href=\"https://seekingalpha.com/news/3239300-match-group-beats-0_05-misses-revenue\" target=\"_blank\">Q4 2016 results</a></strong> &ndash; revenue $319.67M (+19.5% Y/Y,&nbsp;<font color='red'>$0.95 below estimates</font>), EPS $0.29 (<font color='green'>$0.05 above estimates</font>)</li><li>Transaction of sale of The Princeton Review to ST Unitas anticipated for closure in H1 2017.</li><li><strong>Q1 2017 projections</strong> &ndash; revenue $287M-$297M (<a href=\"https://finance.yahoo.com/quote/MTCH/analysts?p=MTCH\" target=\"_blank\">consensus $326.88M</a>), adjusted EBITDA $75M-$80M</li><li><strong>FY 2017 projections</strong> &ndash; revenue $1.260B-$1.305B (consensus $1.4B), adjusted EBITDA $450M-$470M</li><li>Match Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MTCH' title='Match Group, Inc.'>MTCH</a>) chairman and CEO Greg Blatt: \"Match Group executed well in our first full year as a public company. We had strong double digit revenue, operating income, Adjusted EBITDA and PMC growth, generally on track with our expectations at the time we went public. As we roll into 2017, we&rsquo;re confident we can maintain that momentum.\"</li><li><a href=\"http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjU4MDMzfENoaWxkSUQ9MzY0MjYyfFR5cGU9MQ==&amp;t=1\" target=\"_blank\">Investor presentation</a> [pdf]</li><li><a href=\"http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjU4MDM0fENoaWxkSUQ9MzY0MjU3fFR5cGU9MQ==&amp;t=1\" target=\"_blank\">Press release</a> [pdf]</li><li><a href=\"http://edge.media-server.com/m/p/3whgrm5x/lan/en\" target=\"_blank\">Conference call</a></li><li><strong>Update (February 1, 2017)</strong>: IAC (NASDAQ:<a href='https://seekingalpha.com/symbol/IAC' title='IAC/InterActiveCorp'>IAC</a>)&nbsp;<font color='red'>-1.4%</font>&nbsp;pre-market.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3239348\" data-linked=\"Match Group -5.6%; Q1, FY 2017 revenue forecasts below expectations, The Princeton Review divested [updated]\" data-tweet=\"$MTCH $MTCH $IAC - Match Group -5.6%; Q1, FY 2017 revenue forecasts below expectations, The Princeton Review divested [updated] https://seekingalpha.com/news/3239348-match-groupminus-5_6-q1-fy-2017-revenue-forecasts-below-expectations-princeton-review?source=tweet\" data-url=\"https://seekingalpha.com/news/3239348-match-groupminus-5_6-q1-fy-2017-revenue-forecasts-below-expectations-princeton-review\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239211\" data-ts=\"1485903026\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239211-advanced-micro-devicesplus-3_86-q4-2016-results-q2-revenue-view-midpoint-over-projections\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Advanced Micro Devices +3.86%; Q4 2016 results, Q2 revenue view midpoint over projections</a></h4><ul><li><strong><a href=\"https://seekingalpha.com/news/3239275-advanced-micro-devices-beats-0_01-beats-revenue\" target=\"_blank\">Q4 2016 results</a></strong> &ndash; revenue $1.11B (+15.9% Y/Y,&nbsp;<font color='green'>$40M above estimates</font>), EPS -$0.01 (<font color='green'>$0.01 above estimates</font>), operating income $26M (vs. $39M operating loss Y/Y, $70M operating income Q/Q), net loss $8M (vs. $79M net loss Y/Y, $27M net income Q/Q), gross margin 32% (+2 percentage points Y/Y, +1 Q/Q), cash and cash equivalents $1.26B (+$6M from end of Q3 2016)</li><li><strong>Segment revenues</strong> &ndash; Computing and Graphics $600M (+28% Y/Y, +27% Q/Q), Enterprise, Embedded and Semi-Custom $506M (+4% Y/Y, -39% Q/Q)</li><li><strong>Q1 2017 projections</strong> &ndash; revenue -11% Q/Q (+/- 3%), at midpoint +18% Y/Y (<a href=\"https://finance.yahoo.com/quote/AMD/analysts?p=AMD\" target=\"_blank\">consensus $962.72M</a>), gross margin 33%, operating expenses $360M, interest expense, taxes and other $30M, inventory unchanged Q/Q</li><li>Advanced Micro Devices (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) president and CEO Dr. Lisa Su: \"We met our strategic objectives in 2016, successfully executing our product roadmaps, regaining share in key markets, strengthening our financial foundation, and delivering annual revenue growth. As we enter 2017, we are well positioned and on-track to deliver our strongest set of high-performance computing and graphics products in more than a decade.\"</li><li><a href=\"http://quarterlyearnings.amd.com/phoenix.zhtml?c=74093&amp;p=quarterlyearnings\" target=\"_blank\">Additional documents</a></li><li><a href=\"http://edge.media-server.com/m/p/vfmvztx2/lan/en\" target=\"_blank\">Conference call</a></li><li><a href=\"https://seekingalpha.com/pr/16728894-amd-reports-fourth-quarter-annual-2016-financial-results\" target=\"_blank\">Press release</a></li><li><a href=\"https://seekingalpha.com/article/4041237-advanced-micro-devices-inc-2016-q4-results-earnings-call-slides\" target=\"_blank\">Slides</a></li><li><a href=\"https://seekingalpha.com/filing/3377916\" target=\"_blank\">8-K</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3239211\" data-linked=\"Advanced Micro Devices +3.86%; Q4 2016 results, Q2 revenue view midpoint over projections\" data-tweet=\"$AMD - Advanced Micro Devices +3.86%; Q4 2016 results, Q2 revenue view midpoint over projections https://seekingalpha.com/news/3239211-advanced-micro-devicesplus-3_86-q4-2016-results-q2-revenue-view-midpoint-over-projections?source=tweet\" data-url=\"https://seekingalpha.com/news/3239211-advanced-micro-devicesplus-3_86-q4-2016-results-q2-revenue-view-midpoint-over-projections\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239328\" data-ts=\"1485902180\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239328-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/XOMA' title='XOMA Corporation'>XOMA</a> <font color='green'>+9.5%</font>. <a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a> <font color='green'>+4.8%</font>. <a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a> <font color='green'>+3.0%</font>. <a href='https://seekingalpha.com/symbol/CARB' title='Carbonite Inc.'>CARB</a> <font color='green'>+2.9%</font>. <a href='https://seekingalpha.com/symbol/ALGN' title='Align Technology, Inc.'>ALGN</a> <font color='green'>+2.3%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/BOOT' title='Boot Barn Holdings'>BOOT</a> <font color='red'>-11.5%</font>. <a href='https://seekingalpha.com/symbol/SGYP' title='Synergy Pharmaceuticals, Inc.'>SGYP</a> <font color='red'>-9.8%</font>. <a href='https://seekingalpha.com/symbol/MTCH' title='Match Group, Inc.'>MTCH</a> <font color='red'>-7.8%</font>. <a href='https://seekingalpha.com/symbol/NTZ' title='Natuzzi S.p.A.'>NTZ</a> <font color='red'>-6.1%</font>. <a href='https://seekingalpha.com/symbol/MANH' title='Manhattan Associates, Inc.'>MANH</a> <font color='red'>-5.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3239328\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$XOMA $AMD $AAPL - After Hours Gainers / Losers https://seekingalpha.com/news/3239328-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3239328-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239325\" data-ts=\"1485901025\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDT\" target=\"_blank\">MDT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239325-medtronic-preparing-to-jettison-medical-supplies-business-unit-fetch-5b-shares-ahead-1-after\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Medtronic preparing to jettison medical supplies business - unit could fetch $5B; shares ahead 1% after hours</a></h4><ul><li>Bloomberg reports that Medtronic (NYSE:<a href='https://seekingalpha.com/symbol/MDT' title='Medtronic plc'>MDT</a>) is working with advisors on the sale of its medical supplies business, a unit that could fetch as much as $5B if sold in its entirety. Shares are up&nbsp;<font color='green'>1%</font>&nbsp;after hours on robust volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3239325\" data-linked=\"Medtronic preparing to jettison medical supplies business - unit could fetch $5B; shares ahead 1% after hours\" data-tweet=\"$MDT - Medtronic preparing to jettison medical supplies business - unit could fetch $5B; shares ahead 1% after hours https://seekingalpha.com/news/3239325-medtronic-preparing-to-jettison-medical-supplies-business-unit-fetch-5b-shares-ahead-1-after?source=tweet\" data-url=\"https://seekingalpha.com/news/3239325-medtronic-preparing-to-jettison-medical-supplies-business-unit-fetch-5b-shares-ahead-1-after\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239324\" data-ts=\"1485900975\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDT\" target=\"_blank\">MDT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239324-bloomberg-medtronic-putting-medical-supplies-business-on-block\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bloomberg: Medtronic putting medical supplies business on the block</a></h4><ul><li>The company has hired advisers to prep the sale of all or part of its sprawling medical-supplies operation, according to Bloomberg's sources. The unit could be worth as much as $5B, they say.</li><li><a href='https://seekingalpha.com/symbol/MDT' title='Medtronic plc'>MDT</a>&nbsp;<font color='green'>+1.3%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3239324\" data-linked=\"Bloomberg: Medtronic putting medical supplies business on the block\" data-tweet=\"$MDT - Bloomberg: Medtronic putting medical supplies business on the block https://seekingalpha.com/news/3239324-bloomberg-medtronic-putting-medical-supplies-business-on-block?source=tweet\" data-url=\"https://seekingalpha.com/news/3239324-bloomberg-medtronic-putting-medical-supplies-business-on-block\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239322\" data-ts=\"1485900643\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XOMA\" target=\"_blank\">XOMA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239322-xoma-establishes-proof-of-concept-for-product-candidate-358-in-two-rare-metabolic-disorders\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">XOMA establishes proof of concept for product candidate 358 in two rare metabolic disorders; shares up 11% after hours</a></h4><ul><li>(NASDAQ:<a href='https://seekingalpha.com/symbol/XOMA' title='XOMA Corporation'>XOMA</a>) is up&nbsp;<font color='green'>11%</font>&nbsp;after hours on light volume in response to its <a href=\"https://seekingalpha.com/pr/16728826-xoma-establishes-proof-concept-358-congenital-hyperinsulinism-hypoglycemia-post-bariatric\" target=\"_blank\">announcement </a>that it has established proof of concept for product candidate 358 in congenital hyperinsulinism &#40;CHI&#41; and hypoglycemia post-bariatric surgery &#40;PBS&#41;.</li><li>A multi-dose study in children with CHI is set to begin in the UK. A multi-dose study in PBS has been initiated.</li><li>358 is a fully human negative allosteric modulating insulin receptor antibody derived from the company's XMet platform.</li></ul><div class=\"tiny-share-widget\" data-id=\"3239322\" data-linked=\"XOMA establishes proof of concept for product candidate 358 in two rare metabolic disorders; shares up 11% after hours\" data-tweet=\"$XOMA - XOMA establishes proof of concept for product candidate 358 in two rare metabolic disorders; shares up 11% after hours https://seekingalpha.com/news/3239322-xoma-establishes-proof-of-concept-for-product-candidate-358-in-two-rare-metabolic-disorders?source=tweet\" data-url=\"https://seekingalpha.com/news/3239322-xoma-establishes-proof-of-concept-for-product-candidate-358-in-two-rare-metabolic-disorders\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239308\" data-ts=\"1485899246\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGYP\" target=\"_blank\">SGYP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239308-synergy-pharma-readies-equity-offering-shares-down-13-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synergy Pharma readies equity offering; shares down 13% after hours</a></h4><ul><li>Synergy Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SGYP' title='Synergy Pharmaceuticals, Inc.'>SGYP</a>) <a href=\"https://seekingalpha.com/pr/16728842-synergy-pharmaceuticals-announces-proposed-public-offering-common-stock\" target=\"_blank\">initiates </a>a $125M public offering of common stock. Price, volume and terms have yet to be announced. Shares are down&nbsp;<font color='red'>13%</font>&nbsp;after hours on robust volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3239308\" data-linked=\"Synergy Pharma readies equity offering; shares down 13% after hours\" data-tweet=\"$SGYP $SGYP-OLD - Synergy Pharma readies equity offering; shares down 13% after hours https://seekingalpha.com/news/3239308-synergy-pharma-readies-equity-offering-shares-down-13-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3239308-synergy-pharma-readies-equity-offering-shares-down-13-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>107&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239301\" data-ts=\"1485898693\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CATB\" target=\"_blank\">CATB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239301-catabasis-pharmas-edasalonexent-flops-in-randomized-portion-of-mid-stage-dmd-study-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Catabasis Pharma&#39;s edasalonexent flops in randomized portion of mid-stage DMD study; shares crater 58% after hours</a></h4><ul><li><a href=\"https://www.sec.gov/Archives/edgar/data/1454789/000110465917005344/a17-3519_1ex99d1.htm\" target=\"_blank\">Top-line data</a> from Part B of a Phase 2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02439216?term=cat-1004&amp;rank=4\" target=\"_blank\">MoveDMD</a>, assessing Catabasis Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/CATB' title='Catabasis Pharmaceuticals'>CATB</a>) edasalonexent (formerly CAT-1004) for the treatment of Duchenne muscular dystrophy &#40;DMD&#41; failed to show a statistically valid treatment benefit compared to placebo.</li><li>Part B is the randomized, placebo-controlled phase of the study. A total of 31 DMD boys were enrolled. There was no significant change in the primary endpoint of the change from baseline in muscle inflammation in the lower leg muscles as measured by MRI compared to placebo. The high dose cohort (100 mg/kg/day) showed numerical improvement versus placebo across multiple measures but the differences were not statistically significant.</li><li>Edasalonexent inhibits a protein activated in DMD called NF-kB which plays a key role in inflammation and fibrosis.</li><li>Shares are down<font color='red'> 58%</font>&nbsp;after hours on robust volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3239301\" data-linked=\"Catabasis Pharma&#39;s edasalonexent flops in randomized portion of mid-stage DMD study; shares crater 58% after hours\" data-tweet=\"$CATB - Catabasis Pharma&#39;s edasalonexent flops in randomized portion of mid-stage DMD study; shares crater 58% after hours https://seekingalpha.com/news/3239301-catabasis-pharmas-edasalonexent-flops-in-randomized-portion-of-mid-stage-dmd-study-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3239301-catabasis-pharmas-edasalonexent-flops-in-randomized-portion-of-mid-stage-dmd-study-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239294\" data-ts=\"1485898341\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239294-appleplus-2_68-q1-2017-strong\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple +2.68%; Q1 2017 strong</a></h4><ul><li><strong>Q1 2017 results</strong>&nbsp;&ndash; revenue $78.4B (+3.3% Y/Y,&nbsp;<font color='green'>$1.02B above estimates</font>), EPS $3.36 (vs. $3.28 Y/Y,&nbsp;<font color='green'>$0.14 above estimates</font>), operating cash flow $27B, share repurchases and dividends $15B (cumulative payments through capital return program $200B+)</li><li><strong>Products</strong> &ndash; <strong>iPhone</strong>: units 78.29M (+5% Y/Y), revenue $54.378B (+5% Y/Y); <strong>iPad</strong> units 13.081M (-19% Y/Y), revenue $5.533B (-22% Y/Y), <strong>Mac</strong>: units 5.374M (+1% Y/Y), revenue $7.244B (+7% Y/Y); <strong>Services</strong> revenue $7.172B (+18% Y/Y), Other Products [revenue $4.024B (-8% Y/Y).</li><li><strong>Operating segment revenues </strong>&ndash; <strong>Americas</strong> $31.968B (+9% Y/Y), <strong>Europe</strong> $18.521B (+3% Y/Y), <strong>Greater China</strong> $16.233B (<strong>-12% Y/Y</strong>), <strong>Japan</strong> $5.766B (+20% Y/Y), <strong>Rest of Asia Pacific</strong> $5.863B (+8% Y/Y)</li><li><strong>Q2 2017 projections</strong>&nbsp;&ndash; revenue $51.5B-$53.5B (<a href=\"https://finance.yahoo.com/quote/AAPL/analysts?p=AAPL\" target=\"_blank\">consensus $53.94B</a>), gross margin 38%-39%, operating expenses $6.5B-$6.6B, other income/(expense) $400M, tax rate 26%</li><li><strong>Dividend</strong>&nbsp;&ndash; $0.57 per share payable February 16, 2017 to shareholders of record February 13, 2017.</li><li>Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) CEO Tim Cook: \"We&rsquo;re thrilled to report that our holiday quarter results generated Apple&rsquo;s highest quarterly revenue ever, and broke multiple records along the way. We sold more iPhones than ever before and set all-time revenue records for iPhone, Services, Mac and Apple Watch. Revenue from Services grew strongly over last year, led by record customer activity on the App Store, and we are very excited about the products in our pipeline.\"</li><li><a href=\"http://images.apple.com/newsroom/pdfs/Q1FY17ConsolidatedFinancialStatements.pdf\" target=\"_blank\">Consolidated financial statements</a></li><li><a href=\"http://images.apple.com/newsroom/pdfs/Q1FY17DataSummary.pdf\" target=\"_blank\">Data summary</a></li><li><a href=\"http://www.apple.com/investor/earnings-call/\" target=\"_blank\">Conference call</a></li><li><a href=\"http://www.apple.com/newsroom/2017/01/apple-reports-record-first-quarter-results.html\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3239294\" data-linked=\"Apple +2.68%; Q1 2017 strong\" data-tweet=\"$AAPL - Apple +2.68%; Q1 2017 strong https://seekingalpha.com/news/3239294-appleplus-2_68-q1-2017-strong?source=tweet\" data-url=\"https://seekingalpha.com/news/3239294-appleplus-2_68-q1-2017-strong\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>192&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239289\" data-ts=\"1485898201\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ILMN\" target=\"_blank\">ILMN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239289-illumina-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Illumina beats by $0.03, beats on revenue</a></h4><ul><li>Illumina (NASDAQ:<a href='https://seekingalpha.com/symbol/ILMN' title='Illumina, Inc.'>ILMN</a>): Q4 EPS of $0.85 <font color='green'>beats by $0.03</font>.</li><li>Revenue of $619M (+4.6% Y/Y) <font color='green'>beats by $2.59M</font>.</li><li>Shares <font color='green'>+1.2%</font>.</li><li><a href='https://seekingalpha.com/pr/16728928-illumina-reports-full-financial-results-fourth-quarter-fiscal-year-2016'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3239289\" data-linked=\"Illumina beats by $0.03, beats on revenue\" data-tweet=\"$ILMN - Illumina beats by $0.03, beats on revenue https://seekingalpha.com/news/3239289-illumina-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3239289-illumina-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239287\" data-ts=\"1485897910\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/X\" target=\"_blank\">X</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239287-u-s-and-nbsp-steel-beats-0_26-revenue-in-line\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S.&amp;nbsp;Steel beats by $0.26,  revenue in-line</a></h4><ul><li>U.S.&nbsp;Steel (NYSE:<a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a>): Q4 EPS of $0.27 <font color='green'>beats by $0.26</font>.</li><li>Revenue of $2.65B (+3.1% Y/Y) in-line.</li><li>Shares <font color='green'>+5.2%</font>.</li><li><a href='https://seekingalpha.com/pr/16728910-united-states-steel-corporation-reports-improved-2016-results-increased-operating-cash-flow'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3239287\" data-linked=\"U.S.&amp;nbsp;Steel beats by $0.26,  revenue in-line\" data-tweet=\"$X - U.S.&amp;nbsp;Steel beats by $0.26, revenue in-line https://seekingalpha.com/news/3239287-u-s-and-nbsp-steel-beats-0_26-revenue-in-line?source=tweet\" data-url=\"https://seekingalpha.com/news/3239287-u-s-and-nbsp-steel-beats-0_26-revenue-in-line\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239286\" data-ts=\"1485897886\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EA\" target=\"_blank\">EA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239286-electronic-artsminus-1_7-amid-mixed-guidance-ahead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Electronic Arts -1.7% amid mixed guidance ahead</a></h4><ul>   <li>Electronic Arts (NASDAQ:<a href='https://seekingalpha.com/symbol/EA' title='Electronic Arts Inc.'>EA</a>) is <font color='red'>off 1.7%</font> after hours following <a href=\"https://seekingalpha.com/news/3239262-electronic-arts-beats-0_16-misses-revenue\" target=\"_blank\">fiscal Q3 earnings</a> where the company beat expectations by breaking even.</li>    <li>It topped the $1B mark in quarterly operating cash flow for the first time -- a testament, CFO Blake Jorgensen says, to the company's digital live services.</li>    <li>In game highlights, <i>FIFA 17</i> was the year's best-selling console title, and EA says <i>Battlefield 1</i> has a player base more than 50% larger than that of <i>Battlefield 4</i> in its launch quarter.</li>    <li>Digital net sales rose 18% to $2.861B over the trailing 12-month period, making up 60% of total net sales. Digital net sales of $685M for the quarter was 60% of total net revenue of $1.149B.</li>    <li>Revenue breakout: Product, $649M (up 3.8%); Service and other, $500M (up 12.4%).</li>    <li>For full 2017, it sees net revenue of $4.8B (light of expected $4.942B) and EPS of $2.91 (vs. consensus of $2.79). Operating cash flow is forecast at $1.35B. For Q4, it sees net revenue of $1.482B (vs. expected $1.112B) and EPS of $1.64 (above consensus for $1.60).</li>     <li><a href=\"http://ir.ea.com\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16728840-electronic-arts-reports-q3-fy17-financial-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3239286\" data-linked=\"Electronic Arts -1.7% amid mixed guidance ahead\" data-tweet=\"$EA - Electronic Arts -1.7% amid mixed guidance ahead https://seekingalpha.com/news/3239286-electronic-artsminus-1_7-amid-mixed-guidance-ahead?source=tweet\" data-url=\"https://seekingalpha.com/news/3239286-electronic-artsminus-1_7-amid-mixed-guidance-ahead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239269\" data-ts=\"1485897293\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PMD\" target=\"_blank\">PMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239269-psychemedics-says-brazil-distributor-independent-in-country-business-to-continue-usual\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Psychemedics says Brazil distributor independent, in-country business to continue as usual</a></h4><ul><li>In a statement, Psychemedics (NASDAQ:<a href='https://seekingalpha.com/symbol/PMD' title='Psychemedics Corporation'>PMD</a>) says it is <a href=\"https://seekingalpha.com/pr/16728801-psychemedics-corporation-responds-recent-price-volatility\" target=\"_blank\">not involved</a> with the lawsuit between independent distributor Psychemedics Brasil Exames Toxicologicos Ltda. and Omega Labs' representative Laboratorios Omega Brasil Ltda. In other words, whatever financial penalty is imposed, it will be the responsibility of the Brazil organization.</li><li>Psychemedics expects its business in Brazil to continue as usual.</li><li>Shares plunged&nbsp;<font color='red'>28%&nbsp;</font>today on the perception that the company was potentially responsible for paying Omega for lost profits.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3239179-psychemedics-hook-millions-omega-labs-losing-court-case-brazil-shares-plummet-38-percent\" target=\"_blank\">Psychemedics on the hook for \"millions\" to Omega Labs after losing court case in Brazil; shares plummet 38%</a> (Jan. 31)</li></ul><div class=\"tiny-share-widget\" data-id=\"3239269\" data-linked=\"Psychemedics says Brazil distributor independent, in-country business to continue as usual\" data-tweet=\"$PMD - Psychemedics says Brazil distributor independent, in-country business to continue as usual https://seekingalpha.com/news/3239269-psychemedics-says-brazil-distributor-independent-in-country-business-to-continue-usual?source=tweet\" data-url=\"https://seekingalpha.com/news/3239269-psychemedics-says-brazil-distributor-independent-in-country-business-to-continue-usual\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239261\" data-ts=\"1485896987\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIAV\" target=\"_blank\">VIAV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239261-viavi-solutions-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viavi Solutions beats by $0.03, beats on revenue</a></h4><ul><li>Viavi Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/VIAV' title='Viavi Solutions Inc.'>VIAV</a>): FQ2 EPS of $0.10 <font color='green'>beats by $0.03</font>.</li><li>Revenue of $206.5M (-11.0% Y/Y) <font color='green'>beats by $8.77M</font>.</li><li>Shares <font color='green'>+3%</font>.</li><li><a href='https://seekingalpha.com/pr/16728833-viavi-announces-second-quarter-fiscal-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3239261\" data-linked=\"Viavi Solutions beats by $0.03, beats on revenue\" data-tweet=\"$VIAV - Viavi Solutions beats by $0.03, beats on revenue https://seekingalpha.com/news/3239261-viavi-solutions-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3239261-viavi-solutions-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239258\" data-ts=\"1485896940\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SN\" target=\"_blank\">SN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239258-sanchez-energy-to-launch-10m-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sanchez Energy to launch 10M-share offering</a></h4><ul><li>Sanchez Energy (NYSE:<a href='https://seekingalpha.com/symbol/SN' title='Sanchez Energy Corporation'>SN</a>) <font color='red'>-3.8%</font>&nbsp;AH after commencing a <a href=\"https://seekingalpha.com/pr/16728844-sanchez-energy-launches-common-stock-offering\" target=\"_blank\">public offering</a> of 10M common shares, with an underwriters option to purchase up to an additional 1.5M shares.</li><li>SN says it plans to use the proceeds for general  corporate purposes including working capital.</li></ul><div class=\"tiny-share-widget\" data-id=\"3239258\" data-linked=\"Sanchez Energy to launch 10M-share offering\" data-tweet=\"$SN $SNEC - Sanchez Energy to launch 10M-share offering https://seekingalpha.com/news/3239258-sanchez-energy-to-launch-10m-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3239258-sanchez-energy-to-launch-10m-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239251\" data-ts=\"1485896609\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALGN\" target=\"_blank\">ALGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239251-align-technolog-misses-0_07-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Align Technolog misses by $0.07, beats on revenue</a></h4><ul><li>Align Technolog (NASDAQ:<a href='https://seekingalpha.com/symbol/ALGN' title='Align Technology, Inc.'>ALGN</a>): Q4 EPS of $0.59 <font color='red'>misses by $0.07</font>.</li><li>Revenue of $293.2M (+27.3% Y/Y) <font color='green'>beats by $0.8M</font>.</li><li>Shares <font color='green'>+1.4%</font>.</li><li><a href='https://seekingalpha.com/pr/16728814-align-technology-announces-fourth-quarter-year-ended-2016-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3239251\" data-linked=\"Align Technolog misses by $0.07, beats on revenue\" data-tweet=\"$ALGN - Align Technolog misses by $0.07, beats on revenue https://seekingalpha.com/news/3239251-align-technolog-misses-0_07-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3239251-align-technolog-misses-0_07-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239244\" data-ts=\"1485896397\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSAT\" target=\"_blank\">VSAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239244-viasatplus-2_5-after-wells-fargo-upgrades-on-growth-prospects\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ViaSat +2.5% after Wells Fargo upgrades on growth prospects</a></h4><ul>   <li>ViaSat (<a href='https://seekingalpha.com/symbol/VSAT' title='Viasat, Inc.'>VSAT</a> <font color='green'>+2.5%</font>) should see solid growth from upcoming satellite launches, says Wells Fargo in an upgrade to Outperform.</li>    <li>Some higher-than-expected spending on next-gen systems could <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/17/01/8971394/4-ideas-investors-should-accept-before-buying-viasat-sha\" target=\"_blank\">push through to EBITDA growth</a> in the medium and long term, which would pass through to free cash flow, says analyst Andrew Spinola. And the IRR on those systems (ViaSat-2 and ViaSat-3) could come in significantly higher than cost of capital.</li>    <li>In other points to consider, the company could take advantage of consumer broadband demand and leverage a technological advantage in high-throughput satellites. All of that might not be true at once, but \"we believe the risk/reward across the question set is strongly in our favor,&rdquo; he says.</li>    <li>He's cut EPS estimates for 2017 to $1.02 from $1.05, and for 2018 to $0.46 from $0.54. He has a stock valuation range of $94-$98, or 45%-51% upside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3239244\" data-linked=\"ViaSat +2.5% after Wells Fargo upgrades on growth prospects\" data-tweet=\"$VSAT - ViaSat +2.5% after Wells Fargo upgrades on growth prospects https://seekingalpha.com/news/3239244-viasatplus-2_5-after-wells-fargo-upgrades-on-growth-prospects?source=tweet\" data-url=\"https://seekingalpha.com/news/3239244-viasatplus-2_5-after-wells-fargo-upgrades-on-growth-prospects\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239241\" data-ts=\"1485895853\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COMM\" target=\"_blank\">COMM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239241-commscope-sues-clearfield-alleging-infringement-of-13-patents\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CommScope sues Clearfield alleging infringement of 13 patents</a></h4><ul>   <li>CommScope (<a href='https://seekingalpha.com/symbol/COMM' title='CommScope Holding Company Inc.'>COMM</a> <font color='green'>+2.2%</font>) is climbing into the close after noting it's <a href=\"https://seekingalpha.com/pr/16728770-commscope-files-patent-infringement-suit-clearfield\" target=\"_blank\">filed a patent infringement suit</a> against fiber-optic manufacturer Clearfield.</li>    <li>The dispute is over more than a dozen patents tied to CommScope innovations it classifies as \"fiber-to-the-X\" (home, premises, building, etc.)</li>    <li>Demand is driving innovation around cost-effective \"last mile\" deployments, CommScope notes, and it's \"built a deep and extensive portfolio of issued patents related to a wide range of FTTx solutions that simplify fiber network installation, maintenance and management from the central office or head end to the home, business, or other node in the fiber network.&rdquo;</li> </ul><div class=\"tiny-share-widget\" data-id=\"3239241\" data-linked=\"CommScope sues Clearfield alleging infringement of 13 patents\" data-tweet=\"$COMM - CommScope sues Clearfield alleging infringement of 13 patents https://seekingalpha.com/news/3239241-commscope-sues-clearfield-alleging-infringement-of-13-patents?source=tweet\" data-url=\"https://seekingalpha.com/news/3239241-commscope-sues-clearfield-alleging-infringement-of-13-patents\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:50 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239239\" data-ts=\"1485895616\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNX\" target=\"_blank\">CNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239239-consol-energy-ponders-options-for-coal-and-e-and-p-business-separation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consol Energy ponders options for coal and E&amp;P business separation</a></h4><ul>     <li>Consol Energy (<a href='https://seekingalpha.com/symbol/CNX' title='CNX Resources Corporation'>CNX</a> <font color='red'>-7.2%</font>) remains sharply lower after reporting a <a href=\"https://seekingalpha.com/news/3238981-consol-energy-beats-0_01-misses-revenue\" target=\"_blank\">breakeven Q4</a> and a 30% Y/Y revenue decline, and saying it plans to sell its coal business or spin it off to shareholders as soon as this year.</li>     <li>The company, which spun off some of its coal assets to form CNX Coal Resources (<a href='https://seekingalpha.com/symbol/CNXC' title='CNX Coal Resources'>CNXC</a> <font color='red'>-2.8%</font>) in 2015, has been focusing on its oil and gas  business.</li>     <li>In today's <a href=\"https://seekingalpha.com/article/4041136-consol-energy-cnx-q4-2016-results-earnings-call-transcript\" target=\"_blank\">earnings conference call</a>, CNX said it expects to <a href=\"http://www.reuters.com/article/idUSFWN1FL0Q0\" target=\"_blank\">monetize $400M-$600M of assets during 2017</a>.</li>     <li>CNX also says it ended Q4 with <a href=\"http://triblive.com/business/headlines/11871213-74/consol-million-business\" target=\"_blank\">$83M  in net cash</a> from operating activities, compared to $102M at year-end 2015; for full-year 2016, CNX reported net cash of $469M, vs. $506M in 2015.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3239239\" data-linked=\"Consol Energy ponders options for coal and E&amp;P business separation\" data-tweet=\"$CNX $CNX $CNXC - Consol Energy ponders options for coal and E&amp;P business separation https://seekingalpha.com/news/3239239-consol-energy-ponders-options-for-coal-and-e-and-p-business-separation?source=tweet\" data-url=\"https://seekingalpha.com/news/3239239-consol-energy-ponders-options-for-coal-and-e-and-p-business-separation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239237\" data-ts=\"1485895371\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPKE\" target=\"_blank\">SPKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239237-sumzeros-top-analyst-picks-spark-energy-1-short\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SumZero&#39;s top analyst picks Spark Energy as #1 short</a></h4><ul><li>Half Moon Capital founder Eric DeLamarter is the highest-rated analyst at <a href=\"https://sumzero.com/\" target=\"_blank\">SumZero</a>, and he tells Bloomberg he named Spark Energy (<a href='https://seekingalpha.com/symbol/SPKE' title='Spark Energy'>SPKE</a> <font color='red'>-2.4%</font>) as his top short on Jan. 23.</li><li>The news has shaken Spark a bit lower in today's action, and it's now&nbsp;<font color='red'>down more than 12%</font>&nbsp;over the last three sessions.</li></ul><div class=\"tiny-share-widget\" data-id=\"3239237\" data-linked=\"SumZero&#39;s top analyst picks Spark Energy as #1 short\" data-tweet=\"$SPKE - SumZero&#39;s top analyst picks Spark Energy as #1 short https://seekingalpha.com/news/3239237-sumzeros-top-analyst-picks-spark-energy-1-short?source=tweet\" data-url=\"https://seekingalpha.com/news/3239237-sumzeros-top-analyst-picks-spark-energy-1-short\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239235\" data-ts=\"1485895288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239235-biotechs-stage-healthy-reversal-ibb-up-4-from-intraday-low\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biotechs stage healthy reversal; IBB up 4% from intraday low</a></h4><ul><li>Biotechs flex some muscle after an early session Trump-stoked plunge. The iShares Nasdaq Biotech ETF (<a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a> <font color='green'>+2.7%</font>) is up on turnover of more than 2M and up&nbsp;<font color='green'>4%</font>&nbsp;from the intraday low of 267.56.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/BIB' title='ProShares Ultra Nasdaq Biotechnology ETF'>BIB</a>, <a href='https://seekingalpha.com/symbol/BIS' title='ProShares UltraShort Nasdaq Biotechnology ETF'>BIS</a>, <a href='https://seekingalpha.com/symbol/CNCR' title='Loncar Cancer Immunotherapy ETF'>CNCR</a>, <a href='https://seekingalpha.com/symbol/ARKG' title='ARK Genomic Revolution Multi-Sector ETF'>ARKG</a>, <a href='https://seekingalpha.com/symbol/XBI' title='SPDR Biotech ETF'>XBI</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3239235\" data-linked=\"Biotechs stage healthy reversal; IBB up 4% from intraday low\" data-tweet=\"$IBB $BIB $BIS - Biotechs stage healthy reversal; IBB up 4% from intraday low https://seekingalpha.com/news/3239235-biotechs-stage-healthy-reversal-ibb-up-4-from-intraday-low?source=tweet\" data-url=\"https://seekingalpha.com/news/3239235-biotechs-stage-healthy-reversal-ibb-up-4-from-intraday-low\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239234\" data-ts=\"1485894950\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALLY\" target=\"_blank\">ALLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239234-ally-financialplus-7-after-earnings-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ally Financial +7% after earnings beat</a></h4><ul><li>Helping the Q4 bottom line were loan loss provisions of $267M vs. Street estimates of $291M, <a href=\"http://researchwiseny.btig.com/ResearchLibraryAnalec/DownloadResearch.aspx?E=gefbk-b\" target=\"_blank\">says BTIG's bullish Mark Palmer</a>.</li><li>Management expects FY17 EPS growth of less than 15%, but hopefully investors will see this year as one of transition, says Palmer, as the company continues investing in mortgages, credit cards, and online trading. As part of the same presentation (slides here), management promises greater than 15% growth in 2018 and 2019.</li><li>Longer-term, Ally (<a href='https://seekingalpha.com/symbol/ALLY' title='Ally Financial Inc.'>ALLY</a> <font color='green'>+6.8%</font>) has $12B in unsecured debt maturing over the next four years, with a weighted-average cost of 4.7%. Palmer thinks the company is well-positioned to replace that paper with far cheaper deposits.</li><li>He reiterates his Buy rating and $30 price target (another 43% upside).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3239033-ally-financials-q4-beat\" target=\"_blank\">More on Ally Financial's Q4 beat</a> (Jan. 31)</li></ul><div class=\"tiny-share-widget\" data-id=\"3239234\" data-linked=\"Ally Financial +7% after earnings beat\" data-tweet=\"$ALLY - Ally Financial +7% after earnings beat https://seekingalpha.com/news/3239234-ally-financialplus-7-after-earnings-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3239234-ally-financialplus-7-after-earnings-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239226\" data-ts=\"1485892804\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239226-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/LTRX' title='Lantronix, Inc.'>LTRX</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/AVID' title='Avid Technology, Inc.'>AVID</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/I' title='Intelsat SA'>I</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/STRP' title='Straight Path Communications Inc.'>STRP</a> <font color='green'>+8%.</font></li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NCTY' title='The9 Limited'>NCTY</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/RMBS' title='Rambus, Inc.'>RMBS</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/GSAT' title='Globalstar, Inc.'>GSAT</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SMIT' title='Schmitt Industries, Inc.'>SMIT</a> <font color='red'>-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3239226\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$PTI $LTRX $AVID - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3239226-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3239226-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239229\" data-ts=\"1485892670\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIEGY\" target=\"_blank\">SIEGY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239229-siemens-reports-better-expected-fq1-raises-fy-2017-eps-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Siemens reports better than expected FQ1, raises FY 2017 EPS guidance</a></h4><ul><li>Siemens (<a href='https://seekingalpha.com/symbol/SIEGY' title='Siemens AG ADR'>OTCPK:SIEGY</a> <font color='green'>+1.8%</font>) <a href=\"http://www.marketwatch.com/story/siemens-lifts-guidance-after-profit-rises-2017-01-31-144854639\" target=\"_blank\">raises its FY 2017 guidance</a> after reporting FQ1 income from continuing  operations of &euro;1.93B, exceeding the &euro;1.4B  analyst consensus estimate.</li><li>Siemens now sees undiluted EPS at &euro;7.20-&euro;7.70 for the fiscal year ending in September, up from an earlier  forecast of &euro;6.80-&euro;7.20, and raises its outlook for  the earnings margin of its industrial business to 11%-12% from an earlier forecast of 10.5%-11.5%.</li><li>The company says it anticipates \"increasing headwinds for macroeconomic growth and investment  sentiment in our markets due to the complex geopolitical environment... [and] expect(s) modest growth in revenue, net of  effects from currency translation and portfolio transactions.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3239229\" data-linked=\"Siemens reports better than expected FQ1, raises FY 2017 EPS guidance\" data-tweet=\"$SIEGY - Siemens reports better than expected FQ1, raises FY 2017 EPS guidance https://seekingalpha.com/news/3239229-siemens-reports-better-expected-fq1-raises-fy-2017-eps-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3239229-siemens-reports-better-expected-fq1-raises-fy-2017-eps-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239223\" data-ts=\"1485892007\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XOM\" target=\"_blank\">XOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239223-exxon-says-double-permian-basin-production\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Exxon says it could double Permian Basin production</a></h4><ul>     <li>Exxon Mobil (<a href='https://seekingalpha.com/symbol/XOM' title='Exxon Mobil Corporation'>XOM</a> <font color='red'>-1.8%</font>) says it will be able to <a href=\"https://www.ft.com/content/fa9c4126-e7d6-11e6-967b-c88452263daf\" target=\"_blank\">more than double its output in the Permian Basin</a> to 350K boe/day from its current 140K and maintain production at that level for decades.</li>     <li>Such an increase would take shale oil from the Permian and the Bakken formation of North Dakota to 20%-25% of XOM's total production of crude and related liquids, up from 12% today.</li>     <li>XOM also says it <a href=\"http://www.reuters.com/article/us-exxon-mobil-results-idUSKBN15F1JR\" target=\"_blank\">plans $22B in capex for 2017</a>, up 14% Y/Y (which marked a 35% decline) from $19.3B, which the company said in its earnings conference call was not due to rising prices for oilfield contract work or other services,.</li>     <li>XOM also signals that it likely will recognize that as much as 4.6B barrels of its reserves, predominantly in Canada&rsquo;s oil sands, are not profitable to produce, according to SEC rules; in its <a href=\"https://seekingalpha.com/news/3239072-exxon-little-changed-premarket-q4-earnings-miss-revenue-rises\" target=\"_blank\">Q4 results</a>, the company wrote down the value of more than $2B in U.S. assets.</li></ul><div class=\"tiny-share-widget\" data-id=\"3239223\" data-linked=\"Exxon says it could double Permian Basin production\" data-tweet=\"$XOM - Exxon says it could double Permian Basin production https://seekingalpha.com/news/3239223-exxon-says-double-permian-basin-production?source=tweet\" data-url=\"https://seekingalpha.com/news/3239223-exxon-says-double-permian-basin-production\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239212\" data-ts=\"1485889248\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239212-energy-materials-top-5-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RIC' title='Richmont Mines, Inc'>RIC</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/AXU' title='Alexco Resource Corporation'>AXU</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/TGB' title='Taseko Mines Limited'>TGB</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/ASM' title='Avino Silver & Gold Mines Ltd'>ASM</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/SA' title='Seabridge Gold Inc'>SA</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited &#40;New&#41;'>SDRL</a> <font color='red'>-29%</font>. <a href='https://seekingalpha.com/symbol/ESES' title='Eco-Stim Energy Solutions, Inc.'>ESES</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/RYAM' title='Rayonier Advanced Materials'>RYAM</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/NADL' title='North Atlantic Drilling Ltd.'>NADL</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/SM' title='SM Energy Company'>SM</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3239212\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm\" data-tweet=\"$RIC $AXU $TGB - Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3239212-energy-materials-top-5-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3239212-energy-materials-top-5-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239207\" data-ts=\"1485887816\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARRS\" target=\"_blank\">ARRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239207-arris-drops-3_2-comcast-makes-xfinity-service-available-through-roku\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arris drops 3.2% as Comcast makes Xfinity service available through Roku</a></h4><ul>   <li>Arris (NASDAQ:<a href='https://seekingalpha.com/symbol/ARRS' title='ARRIS International plc'>ARRS</a>) takes a tumble, <font color='red'>falling more than 9%</font> before yo-yo-ing back to a <font color='red'>drop of 3.2%</font>, on word that Comcast (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>) -- Arris' biggest customer, making up 21% of its revenue -- is pushing its Xfinity TV through an app to those with Roku boxes.</li>    <li>That makes Roku the first third-party box to be able to offer Xfinity. Comcast previously announced Samsung as its first smart TV&nbsp;partner in its program.</li>    <li>Subscribers who choose to use their Rokus rather than Comcast's Arris boxes will need to hang onto both through a test period, Comcast says, but later this year, customers can sign up without renting a cable box.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3225154-white-house-changing-set-top-box-reform-may-life-support\" target=\"_blank\">With White House changing, set-top box reform may be on life support</a> (Nov. 16 2016)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3239207\" data-linked=\"Arris drops 3.2% as Comcast makes Xfinity service available through Roku\" data-tweet=\"$ARRS $ARRS $CMCSA - Arris drops 3.2% as Comcast makes Xfinity service available through Roku https://seekingalpha.com/news/3239207-arris-drops-3_2-comcast-makes-xfinity-service-available-through-roku?source=tweet\" data-url=\"https://seekingalpha.com/news/3239207-arris-drops-3_2-comcast-makes-xfinity-service-available-through-roku\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239204\" data-ts=\"1485887084\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DUK\" target=\"_blank\">DUK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239204-utilities-on-move-rest-of-s-and-p-and-bond-yields-decline\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Utilities on the move as rest of S&amp;P and bond yields decline</a></h4><ul><li>Alongside a flow of money<a href=\"https://seekingalpha.com/news/3239180-big-session-reits-averages-rates-slip\" target=\"_blank\"> into REITs</a>, the utilities (<a href='https://seekingalpha.com/symbol/XLU' title='Utilities Select Sector SPDR ETF'>XLU</a> <font color='green'>+1.4%</font>) are seeing plenty of buying interest today.</li><li>The S&amp;P 500 is&nbsp;<font color='red'>down 0.5%</font>&nbsp;and the 10-year Treasury yield is lower by 4.3 basis points to 2.445%.</li><li>Duke Energy (<a href='https://seekingalpha.com/symbol/DUK' title='Duke Energy Corporation'>DUK</a> <font color='green'>+1.7%</font>), NextEra (<a href='https://seekingalpha.com/symbol/NEE' title='NextEra Energy, Inc.'>NEE</a> <font color='green'>+1.1%</font>), Southern Co. (<a href='https://seekingalpha.com/symbol/SO' title='Southern Company'>SO</a> <font color='green'>+1.7%</font>), Dominion Resources (<a href='https://seekingalpha.com/symbol/D' title='Dominion Energy, Inc.'>D</a> <font color='green'>+1.1%</font>), American Electric Power (<a href='https://seekingalpha.com/symbol/AEP' title='American Electric Power Company Inc'>AEP</a> <font color='green'>+1.2%</font>), PG&amp;E (<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a> <font color='green'>+2%</font>), PPL Corp (<a href='https://seekingalpha.com/symbol/PPL' title='PPL Corporation'>PPL</a> <font color='green'>+1.3%</font>)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLU' title='Utilities Select Sector SPDR ETF'>XLU</a>, <a href='https://seekingalpha.com/symbol/UTG' title='Reaves Utility Income Fund'>UTG</a>, <a href='https://seekingalpha.com/symbol/IDU' title='iShares U.S. Utilities ETF'>IDU</a>, <a href='https://seekingalpha.com/symbol/VPU' title='Vanguard Utilities ETF'>VPU</a>, <a href='https://seekingalpha.com/symbol/GUT' title='Gabelli Utility Trust'>GUT</a>, <a href='https://seekingalpha.com/symbol/BUI' title='BlackRock Utility&Infrastructure Trust'>BUI</a>, <a href='https://seekingalpha.com/symbol/FUTY' title='Fidelity MSCI Utilities Index ETF'>FUTY</a>, <a href='https://seekingalpha.com/symbol/RYU' title='Invesco S&P Equal Weight Utilities ETF'>RYU</a>, <a href='https://seekingalpha.com/symbol/UPW' title='ProShares Ultra Utilities ETF'>UPW</a>, <a href='https://seekingalpha.com/symbol/FXU' title='First Trust Utilities AlphaDEX ETF'>FXU</a>, <a href='https://seekingalpha.com/symbol/SDP' title='ProShares UltraShort Utilities ETF'>SDP</a>, <a href='https://seekingalpha.com/symbol/FUGAX' title='Fidelity Advisor® Utilities Fund A'>FUGAX</a>, <a href='https://seekingalpha.com/symbol/JHMU' title='John Hancock Multifactor Utilities ETF'>JHMU</a>, <a href='https://seekingalpha.com/symbol/UTLF' title='iShares Edge MSCI Multifactor Utilities ETF'>UTLF</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3239204\" data-linked=\"Utilities on the move as rest of S&amp;P and bond yields decline\" data-tweet=\"$DUK $XLU $DUK - Utilities on the move as rest of S&amp;P and bond yields decline https://seekingalpha.com/news/3239204-utilities-on-move-rest-of-s-and-p-and-bond-yields-decline?source=tweet\" data-url=\"https://seekingalpha.com/news/3239204-utilities-on-move-rest-of-s-and-p-and-bond-yields-decline\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239203\" data-ts=\"1485886532\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VLO\" target=\"_blank\">VLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239203-valerominus-4-record-biofuels-compliance-costs-to-continue-in-2017\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Valero -4% as record biofuels compliance costs to continue in 2017</a></h4><ul>     <li>Valero Energy (<a href='https://seekingalpha.com/symbol/VLO' title='Valero Energy Corporation'>VLO</a> <font color='red'>-4%</font>) sinks even after reporting better than expected <a href=\"https://seekingalpha.com/news/3238985-valero-energy-beats-0_04-beats-revenue\" target=\"_blank\">Q4 earnings</a> and revenues, as its bottom line continues to suffer from higher ethanol fuel blending costs.</li>     <li>VLO says its fuel blending costs - mostly derived from RINs - totaled $217M in Q4, bringing its full-year fuel blending cost to $749M, <a href=\"http://www.mysanantonio.com/business/eagle-ford-energy/article/Valero-Energy-Corp-4Q-profit-rises-5-3-percent-10896797.php\" target=\"_blank\">70% higher</a> than $440M in 2015 and even above the $517M spent in 2013 when RINs soared to record highs.</li>     <li>Signaling that record high costs to comply with the U.S. renewable fuels program <a href=\"http://www.reuters.com/article/us-valero-energy-results-biofuels-idUSKBN15F28S\" target=\"_blank\">will continue this year</a>, VLO President/CEO Joe Gorder calls it \"a significant issue for us, so we continue to work aggressively with regulators\" during today's earnings conference call.</li><li>VLO also forecasts FY 2017 capex of ~$1.7B, including $1.1B for growth projects.</li><li>Refiners are lower across the board: <a href='https://seekingalpha.com/symbol/PSX' title='Phillips 66'>PSX</a> <font color='red'>-0.8%</font>, TSO <font color='red'>-3.7%</font>, <a href='https://seekingalpha.com/symbol/MPC' title='Marathon Petroleum Corp.'>MPC</a> <font color='red'>-1%</font>, <a href='https://seekingalpha.com/symbol/WNR' title='Western Refining, Inc.'>WNR</a> <font color='red'>-2.9%</font>, <a href='https://seekingalpha.com/symbol/HFC' title='HollyFrontier Corp.'>HFC</a> <font color='red'>-1.8%</font>, <a href='https://seekingalpha.com/symbol/PBF' title='PBF Energy'>PBF</a> <font color='red'>-2.1%</font>, <a href='https://seekingalpha.com/symbol/DK' title='Delek US Holdings, Inc.'>DK</a> <font color='red'>-2.2%</font>, <a href='https://seekingalpha.com/symbol/ALJ' title='Alon USA Energy, Inc.'>ALJ</a> <font color='red'>-1.9%</font>, <a href='https://seekingalpha.com/symbol/CVI' title='CVR Energy, Inc.'>CVI</a> <font color='red'>-0.4%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3239203\" data-linked=\"Valero -4% as record biofuels compliance costs to continue in 2017\" data-tweet=\"$VLO $VLO $PSX - Valero -4% as record biofuels compliance costs to continue in 2017 https://seekingalpha.com/news/3239203-valerominus-4-record-biofuels-compliance-costs-to-continue-in-2017?source=tweet\" data-url=\"https://seekingalpha.com/news/3239203-valerominus-4-record-biofuels-compliance-costs-to-continue-in-2017\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239201\" data-ts=\"1485886353\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RRTS\" target=\"_blank\">RRTS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239201-roadrunner-transportation-dives-after-disclosing-accounting-issues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roadrunner Transportation dives after disclosing accounting issues</a></h4><ul><li>Roadrunner Transportation (NYSE:<a href='https://seekingalpha.com/symbol/RRTS' title='Roadrunner Transportation Systems, Inc.'>RRTS</a>) is&nbsp;<font color='red'>down 33%</font>&nbsp;after the company disclosed it made accounting errors that will require adjustments to prior results of $20M to $25M.</li><li>A significant goodwill impairment charge is also being taken by the company.</li><li>On Wall Street, Stifel Nicolaus suspended its coverage on RRTS and warned of downwide risk to $0 if the accounting probe widens.</li><li><a href=\"https://seekingalpha.com/filing/3376223\" target=\"_blank\">SEC Form 8-K</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3239201\" data-linked=\"Roadrunner Transportation dives after disclosing accounting issues\" data-tweet=\"$RRTS - Roadrunner Transportation dives after disclosing accounting issues https://seekingalpha.com/news/3239201-roadrunner-transportation-dives-after-disclosing-accounting-issues?source=tweet\" data-url=\"https://seekingalpha.com/news/3239201-roadrunner-transportation-dives-after-disclosing-accounting-issues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239190\" data-ts=\"1485885623\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239190-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CFBK' title='Central Federal Corporation'>CFBK</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/TCBK' title='Trico Bancshares'>TCBK</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/KRNY' title='Kearny Financial'>KRNY</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/ALLY' title='Ally Financial Inc.'>ALLY</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/FNBC' title='First NBC Bank Holding Company'>OTC:FNBC</a> <font color='red'>-31%</font>. <a href='https://seekingalpha.com/symbol/CASH' title='Meta Financial Group, Inc.'>CASH</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/TBBK' title='The Bancorp, Inc.'>TBBK</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3239190\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$CFBK $TCBK $KRNY - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3239190-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3239190-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239195\" data-ts=\"1485885413\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TUP\" target=\"_blank\">TUP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239195-tupperwareplus-3_3-ahead-of-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tupperware +3.3% ahead of earnings</a></h4><ul><li>B. Riley's Linda Bolton pulls her Sell rating on Tupperware (<a href='https://seekingalpha.com/symbol/TUP' title='Tupperware Brands Corporation'>TUP</a> <font color='green'>+3.3%</font>) as she isn't expecting the company to guide 2017 EPS below expectations when it reports tomorrow.</li><li>Bolton had previously downgraded to Sell on Nov. 28, and the stock's&nbsp;<font color='green'>ahead about 3%</font>&nbsp;since.</li></ul><div class=\"tiny-share-widget\" data-id=\"3239195\" data-linked=\"Tupperware +3.3% ahead of earnings\" data-tweet=\"$TUP - Tupperware +3.3% ahead of earnings https://seekingalpha.com/news/3239195-tupperwareplus-3_3-ahead-of-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3239195-tupperwareplus-3_3-ahead-of-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239194\" data-ts=\"1485885257\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIC\" target=\"_blank\">RIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239194-richmont-minesplus-10-island-gold-mine-mineral-reserves-rise-34\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Richmont Mines +10% as Island Gold Mine mineral reserves rise 34%</a></h4><ul><li>Richmont Mines (<a href='https://seekingalpha.com/symbol/RIC' title='Richmont Mines, Inc'>RIC</a> <font color='green'>+10.1%</font>) shoots higher after reporting 2016 mineral reserves and resources, with mineral reserves at the Island Gold  Mine in Ontario <a href=\"https://seekingalpha.com/pr/16727624-richmont-reports-2016-mineral-reserves-and-resources\" target=\"_blank\">rising by 34%</a> to 752K oz. of gold at an 11% higher grade of 9.17 grams/ton.</li><li>Year-end inferred resources of 995K gold oz. represent a 30% Y/Y increase at a 20% higher grade of  10.18 grams/ton, at an average discovery cost of less than $35/oz.</li><li>RIC says its drilling program also has successfully  contributed to a 30% increase in inferred  resources at a 20% higher grade.</li></ul><div class=\"tiny-share-widget\" data-id=\"3239194\" data-linked=\"Richmont Mines +10% as Island Gold Mine mineral reserves rise 34%\" data-tweet=\"$RIC - Richmont Mines +10% as Island Gold Mine mineral reserves rise 34% https://seekingalpha.com/news/3239194-richmont-minesplus-10-island-gold-mine-mineral-reserves-rise-34?source=tweet\" data-url=\"https://seekingalpha.com/news/3239194-richmont-minesplus-10-island-gold-mine-mineral-reserves-rise-34\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:54 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239192\" data-ts=\"1485885100\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NRZ\" target=\"_blank\">NRZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239192-compass-point-buys-dip-in-new-residential\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Compass Point buys the dip in New Residential</a></h4><ul><li>With New Residential (<a href='https://seekingalpha.com/symbol/NRZ' title='New Residential Investment Corp.'>NRZ</a> <font color='red'>-3.1%</font>) now<font color='red'> lower by nearly 7%</font>&nbsp;since the deal to purchase $97B UPB of MSRs from CitiMortgage and the associated whopper of a capital raise, Compass Point's Fred Small <a href=\"https://www.marketbeat.com/stocks/NYSE/NRZ/?RegistrationCode=SocialMedia-Twitter&amp;utm_source=GeneralSocialMedia&amp;utm_medium=Social\" target=\"_blank\">upgrades to Buy</a> from Neutral.</li><li>Encouraging to the longs is a massive 37.5M shares in NRZ traded so far today (vs. average of 2.35M).</li></ul><div class=\"tiny-share-widget\" data-id=\"3239192\" data-linked=\"Compass Point buys the dip in New Residential\" data-tweet=\"$NRZ - Compass Point buys the dip in New Residential https://seekingalpha.com/news/3239192-compass-point-buys-dip-in-new-residential?source=tweet\" data-url=\"https://seekingalpha.com/news/3239192-compass-point-buys-dip-in-new-residential\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>52&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239189\" data-ts=\"1485884829\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239189-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='green'>+94%</font>. <a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/DCIX' title='Diana Containerships Inc.'>DCIX</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/MNTA' title='Momenta Pharmaceuticals, Inc.'>MNTA</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/LTRX' title='Lantronix, Inc.'>LTRX</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/AVID' title='Avid Technology, Inc.'>AVID</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/STRP' title='Straight Path Communications Inc.'>STRP</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/NTZ' title='Natuzzi S.p.A.'>NTZ</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/TLYS' title='Tilly&#39;s, Inc.'>TLYS</a> <font color='green'>+11%</font>. SSH <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TENX' title='Tenax Therapeutics, Inc.'>TENX</a> <font color='red'>-77%</font>. <a href='https://seekingalpha.com/symbol/DMTX' title='Dimension Therapeutics'>DMTX</a> <font color='red'>-50%</font>. <a href='https://seekingalpha.com/symbol/PMD' title='Psychemedics Corporation'>PMD</a> <font color='red'>-40%</font>. <a href='https://seekingalpha.com/symbol/RRTS' title='Roadrunner Transportation Systems, Inc.'>RRTS</a> <font color='red'>-33%</font>. <a href='https://seekingalpha.com/symbol/FNBC' title='First NBC Bank Holding Company'>OTC:FNBC</a> <font color='red'>-33%</font>. <a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited &#40;New&#41;'>SDRL</a> <font color='red'>-27%</font>. <a href='https://seekingalpha.com/symbol/UAA' title='Under Armour, Inc.'>UAA</a> <font color='red'>-25%</font>. <a href='https://seekingalpha.com/symbol/UA' title='Under Armour, Inc. Class C'>UA</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/RYAM' title='Rayonier Advanced Materials'>RYAM</a> <font color='red'>-17%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3239189\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$DRYS $AEZS $DCIX - Midday Gainers / Losers https://seekingalpha.com/news/3239189-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3239189-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239186\" data-ts=\"1485884780\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TENX\" target=\"_blank\">TENX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239186-tenax-therapeutics-lead-product-candidate-flunks-late-state-study-shares-plummet-77\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tenax Therapeutics&#39; lead product candidate flunks late-state study; shares plummet 77%</a></h4><ul><li>Nano cap Tenax Therapeutics (<a href='https://seekingalpha.com/symbol/TENX' title='Tenax Therapeutics, Inc.'>TENX</a> <font color='red'>-76.9%</font>) craters on a 22x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/16728140-tenax-therapeutics-announces-top-line-results-phase-3-levo-cts-trial-cardiac-surgery\" target=\"_blank\">announcement </a>that lead product candidate levosimendan failed to beat placebo in a Phase 3 clinical trial (LEVO-CTS) assessing the use of the calcium sensitizer administered during cardiac surgery to reduce the incidence of low cardiac output syndrome and associated morbidity and mortality.</li><li>Levosimendan failed to demonstrate a statistically valid treatment benefit versus placebo as determined by all-cause mortality at day 30 following surgery or the use of a mechanical assist device through day 5.</li><li>Detailed data will be presented at the American College of Cardiology 66th Annual Scientific Session on Sunday, March 19 in Washington, D.C.</li></ul><div class=\"tiny-share-widget\" data-id=\"3239186\" data-linked=\"Tenax Therapeutics&#39; lead product candidate flunks late-state study; shares plummet 77%\" data-tweet=\"$TENX - Tenax Therapeutics&#39; lead product candidate flunks late-state study; shares plummet 77% https://seekingalpha.com/news/3239186-tenax-therapeutics-lead-product-candidate-flunks-late-state-study-shares-plummet-77?source=tweet\" data-url=\"https://seekingalpha.com/news/3239186-tenax-therapeutics-lead-product-candidate-flunks-late-state-study-shares-plummet-77\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239179\" data-ts=\"1485883474\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PMD\" target=\"_blank\">PMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239179-psychemedics-on-hook-for-millions-to-omega-labs-after-losing-court-case-in-brazil-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Psychemedics on the hook for &quot;millions&quot; to Omega Labs after losing court case in Brazil; shares plummet 38%</a></h4><ul><li>Thinly traded nano cap Psychemedics (<a href='https://seekingalpha.com/symbol/PMD' title='Psychemedics Corporation'>PMD</a> <font color='red'>-38.3%</font>) craters on almost a 20x surge in volume, albeit on turnover of less than 600K shares, in apparent response to <a href=\"https://seekingalpha.com/pr/16727559-figueira-hong-amaral-bertoni-advogados-landmark-legal-ruling-orders-psychemedics-brazil\" target=\"_blank\">litigation </a>in Brazil between the company's local representative, Psychemedics Brasil Exames Toxicologicos Ltda. and Omega Laboratories' representative Laboratorios Omega Brasil Ltda. The latter accused the former of using anti-competitive practices to keep it out of the Brazilian hair drug testing market.</li><li>Omega prevailed in the case which stipulates that Psychemedics must compensate it for lost profits. The specific amount has not been released, but it is expected to be \"in the millions of (U.S.) dollars.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3239179\" data-linked=\"Psychemedics on the hook for &quot;millions&quot; to Omega Labs after losing court case in Brazil; shares plummet 38%\" data-tweet=\"$PMD - Psychemedics on the hook for &quot;millions&quot; to Omega Labs after losing court case in Brazil; shares plummet 38% https://seekingalpha.com/news/3239179-psychemedics-on-hook-for-millions-to-omega-labs-after-losing-court-case-in-brazil-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3239179-psychemedics-on-hook-for-millions-to-omega-labs-after-losing-court-case-in-brazil-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239180\" data-ts=\"1485882974\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPG\" target=\"_blank\">SPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239180-big-session-for-reits-averages-and-rates-slip\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Big session for REITs as averages and rates slip</a></h4><ul><li>Among the biggest gainers are mall players Simon Property Group (<a href='https://seekingalpha.com/symbol/SPG' title='Simon Property Group, Inc.'>SPG</a> <font color='green'>+3%</font>) and General Growth Properties (GGP <font color='green'>+4.2%</font>) after both posted solid Q4 results amid a tough retail environment.</li><li>The iShares Dow Jones U.S. Real Estate ETF (<a href='https://seekingalpha.com/symbol/IYR' title='iShares U.S. Real Estate ETF'>IYR</a> <font color='green'>+1.1%</font>) and the Vanguard REIT Index Fund (<a href='https://seekingalpha.com/symbol/VNQ' title='Vanguard Real Estate ETF'>VNQ</a> <font color='green'>+1.3%</font>) are both advancing alongside the S&amp;P 500's&nbsp;<font color='red'>0.5% decline</font>&nbsp;and a four basis point dip in the 10-year Treasury yield.</li><li>Other mall names: Kimco (<a href='https://seekingalpha.com/symbol/KIM' title='Kimco Realty Corporation'>KIM</a> <font color='green'>+1.2%</font>), Weingarten (<a href='https://seekingalpha.com/symbol/WRI' title='Weingarten Realty Investors'>WRI</a> <font color='green'>+1.3%</font>), Macerich (<a href='https://seekingalpha.com/symbol/MAC' title='Macerich Co.'>MAC</a> <font color='green'>+1.8%</font>), PREIT (<a href='https://seekingalpha.com/symbol/PEI' title='Pennsylvania Real Estate Investment Trust'>PEI</a> <font color='green'>+4.1%</font>)</li><li>Other REITs of note: National Retail (<a href='https://seekingalpha.com/symbol/NNN' title='National Retail Properties, Inc.'>NNN</a> <font color='green'>+3.1%</font>), Omega Healthcare (<a href='https://seekingalpha.com/symbol/OHI' title='Omega Healthcare Investors, Inc'>OHI</a> <font color='green'>+0.7%</font>), HCP (<a href='https://seekingalpha.com/symbol/HCP' title='HCP, Inc.'>HCP</a> <font color='green'>+2.2%</font>), Equity Residential (<a href='https://seekingalpha.com/symbol/EQR' title='Equity Residential'>EQR</a> <font color='green'>+1.2%</font>), UDR (<a href='https://seekingalpha.com/symbol/UDR' title='UDR, Inc.'>UDR</a> <font color='green'>+1.9%</font>), CubeSmart (<a href='https://seekingalpha.com/symbol/CUBE' title='CubeSmart Common Shares'>CUBE</a> <font color='green'>+0.9%</font>), Boston Properties (<a href='https://seekingalpha.com/symbol/BXP' title='Boston Properties, Inc.'>BXP</a> <font color='green'>+1.1%</font>), Stag Industrial (<a href='https://seekingalpha.com/symbol/STAG' title='STAG Industrial, Inc.'>STAG</a> <font color='green'>+2%</font>), Gramercy Property (<a href='https://seekingalpha.com/symbol/GPT' title='Gramercy Property Trust, Inc.'>GPT</a> <font color='green'>+1.6%</font>)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3239069-simon-property-beats-boosts-dividend-sees-10-percent-ffo-growth-2017\" target=\"_blank\">Simon Property beats, boosts dividend, sees 10% FFO growth in 2017</a> (Jan. 31)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3238842-general-growth-properties-1_2-percent-q4-results-2017-guidance\" target=\"_blank\">General Growth Properties up 1.2% after Q4 results, 2017 guidance</a> (Jan. 30)</li></ul><div class=\"tiny-share-widget\" data-id=\"3239180\" data-linked=\"Big session for REITs as averages and rates slip\" data-tweet=\"$SPG $SPG $BPR - Big session for REITs as averages and rates slip https://seekingalpha.com/news/3239180-big-session-for-reits-averages-and-rates-slip?source=tweet\" data-url=\"https://seekingalpha.com/news/3239180-big-session-for-reits-averages-and-rates-slip\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239178\" data-ts=\"1485882205\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239178-gold-closing-out-best-month-since-june\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gold closing out best month since June</a></h4><ul><li>A bit of political instability, at least a little money exiting equities, and a sliding dollar has gold&nbsp;<font color='green'>up another 1.6%</font>&nbsp;today to $1,215 per ounce. Should it hold there, the price of the metal would <a href=\"http://www.marketwatch.com/story/gold-pitches-up-on-track-for-best-monthly-gain-since-june-2017-01-31\" target=\"_blank\">post a gain of more than</a>&nbsp;<font color='green'>5%</font>&nbsp;for January.</li><li>\"This pit-stop in the equity markets, combined with the falling USD and Treasury yields in the broader market is all contributing,\" says Adam Koos of Libertas Wealth Management Group.</li><li>It's been a busy news cycle, so this may have been overlooked, but the FOMC begins its two-day policy meeting today. No change is expected, but the policy statement tomorrow afternoon might halt or push further the gold rally.</li><li><a href='https://seekingalpha.com/symbol/GLD' title='SPDR Gold Trust ETF'>GLD</a>&nbsp;<font color='green'>+1.45%</font></li><li>ETFs: <a href='https://seekingalpha.com/symbol/GLD' title='SPDR Gold Trust ETF'>GLD</a>, <a href='https://seekingalpha.com/symbol/IAU' title='iShares Gold Trust ETF'>IAU</a>, <a href='https://seekingalpha.com/symbol/PHYS' title='Sprott Physical Gold Trust'>PHYS</a>, <a href='https://seekingalpha.com/symbol/SGOL' title='ETFS Physical Swiss Gold Trust ETF'>SGOL</a>, <a href='https://seekingalpha.com/symbol/UGL' title='ProShares Ultra Gold ETF'>UGL</a>, <a href='https://seekingalpha.com/symbol/DGP' title='DB Gold Double Long ETN'>DGP</a>, <a href='https://seekingalpha.com/symbol/GTU' title='Central Gold-Trust'>GTU</a>, <a href='https://seekingalpha.com/symbol/UGLD' title='VelocityShares 3x Long Gold ETN'>UGLD</a>, <a href='https://seekingalpha.com/symbol/GLL' title='ProShares UltraShort Gold ETF'>GLL</a>, <a href='https://seekingalpha.com/symbol/DZZ' title='DB Gold Double Short ETN'>DZZ</a>, <a href='https://seekingalpha.com/symbol/GLDI' title='Credit Suisse Gold Shares Covered Call ETN'>GLDI</a>, <a href='https://seekingalpha.com/symbol/OUNZ' title='VanEck Merk Gold Trust ETF'>OUNZ</a>, <a href='https://seekingalpha.com/symbol/DGL' title='PowerShares DB Gold ETF'>DGL</a>, <a href='https://seekingalpha.com/symbol/DGZ' title='DB Gold Short ETN'>DGZ</a>, <a href='https://seekingalpha.com/symbol/DGLD' title='VelocityShares 3x Inverse Gold ETN'>DGLD</a>, <a href='https://seekingalpha.com/symbol/GYEN' title='AdvisorShares Gartman Gold/Yen ETF'>GYEN</a>, <a href='https://seekingalpha.com/symbol/GEUR' title='AdvisorShares Gartman Gold/Euro ETF'>GEUR</a>, <a href='https://seekingalpha.com/symbol/UBG' title='UBS ETRACS CMCI Gold Total Return ETN'>UBG</a>, <a href='https://seekingalpha.com/symbol/QGLDX' title='The Gold Bullion Strategy Fund Inv'>QGLDX</a>, <a href='https://seekingalpha.com/symbol/GLDW' title='SPDR Long Dollar Gold Trust ETF'>GLDW</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3239178\" data-linked=\"Gold closing out best month since June\" data-tweet=\"$GLD $IAU $PHYS - Gold closing out best month since June https://seekingalpha.com/news/3239178-gold-closing-out-best-month-since-june?source=tweet\" data-url=\"https://seekingalpha.com/news/3239178-gold-closing-out-best-month-since-june\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239175\" data-ts=\"1485881985\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239175-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NTZ' title='Natuzzi S.p.A.'>NTZ</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/ICON' title='Iconix Brand Group, Inc.'>ICON</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/UAA' title='Under Armour, Inc.'>UAA</a> <font color='red'>-24%</font>. <a href='https://seekingalpha.com/symbol/UA' title='Under Armour, Inc. Class C'>UA</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/SPAR' title='Spartan Motors, Inc.'>SPAR</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/FBR' title='Fibria Celulose S.A.'>FBR</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/PME' title='Pingtan Marine Enterprise Ltd.'>PME</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3239175\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$NTZ $ICON $UAA - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3239175-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3239175-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239173\" data-ts=\"1485881293\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYDY\" target=\"_blank\">CYDY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239173-cytodyn-commences-1_2m-direct-capital-raise-shares-ease-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CytoDyn commences $1.2M direct capital raise; shares ease 3%</a></h4><ul><li>CytoDyn (<a href='https://seekingalpha.com/symbol/CYDY' title='CytoDyn Inc.'>OTCQB:CYDY</a> <font color='red'>-3.3%</font>) inks <a href=\"https://www.sec.gov/Archives/edgar/data/1175680/000119312517024571/d324149d8k.htm\" target=\"_blank\">agreements </a>with certain investors for the direct placement of 1,534,999 shares of common stock at $0.75/share. Buyers will also receive five-year warrants to purchase 767,498 shares of common at $1.</li><li>Net proceeds of ~$1M will fund clinical trials and general corporate purposes. Closing date is today.</li><li>Yesterday's close was $0.73.</li></ul><div class=\"tiny-share-widget\" data-id=\"3239173\" data-linked=\"CytoDyn commences $1.2M direct capital raise; shares ease 3%\" data-tweet=\"$CYDY - CytoDyn commences $1.2M direct capital raise; shares ease 3% https://seekingalpha.com/news/3239173-cytodyn-commences-1_2m-direct-capital-raise-shares-ease-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3239173-cytodyn-commences-1_2m-direct-capital-raise-shares-ease-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239172\" data-ts=\"1485881085\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAA\" target=\"_blank\">BAA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239172-banro-enters-support-agreement-to-refinance-207m-debt\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Banro enters support agreement to refinance $207M debt</a></h4><ul>     <li>Banro (<a href='https://seekingalpha.com/symbol/BAA' title='Banro Corporation'>BAA</a> <font color='red'>-24.4%</font>) says it has entered into a <a href=\"https://seekingalpha.com/pr/16728460-banro-announces-execution-support-agreement-recapitalization-transactions\" target=\"_blank\">support agreement</a> with major stakeholders to refinance $207.5M of outstanding debt, equitizing outstanding preferred shares and  raising $45M via a gold forward sale.</li>     <li>BAA expects the recapitalization to reduce debt, improve liquidity and allow it to optimize operations and enhance its gold mining assets in the Democratic Republic of the Congo.</li>     <li>BAA will implement the plan through a corporate plan of arrangement under the Canada Business Corporations Act.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3239172\" data-linked=\"Banro enters support agreement to refinance $207M debt\" data-tweet=\"$BAA - Banro enters support agreement to refinance $207M debt https://seekingalpha.com/news/3239172-banro-enters-support-agreement-to-refinance-207m-debt?source=tweet\" data-url=\"https://seekingalpha.com/news/3239172-banro-enters-support-agreement-to-refinance-207m-debt\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239171\" data-ts=\"1485881059\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIG\" target=\"_blank\">AIG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239171-aigminus-1_1-s-and-p-downgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AIG -1.1% as S&amp;P downgrades</a></h4><ul><li>\"We no longer believe AIG (<a href='https://seekingalpha.com/symbol/AIG' title='American International Group Inc'>AIG</a> <font color='red'>-1.1%</font>) will meet our fixed-charge coverage threshold to support nonstandard notching between operating subsidiaries and the holding company,\" <a href=\"http://now.eloqua.com/es.asp?s=302554905&amp;e=359791&amp;elq=aa3de7feb45e48209b8c38c7cd85d2f1\" target=\"_blank\">says S&amp;P, cutting</a> the insurer's rating to BBB+ from A-. The outlook is stable.</li><li>The rating on AIG's operating subsidiaries remain at A+.</li><li>S&amp;P expects AIG will fall short of a 7x-8x fixed-charge coverage ratio for 2016-17, says the agency's Tracy Dolin, noting the Q4 reserve charge the company announced as part of its reinsurance deal earlier this month.</li><li>Thanks to ongoing challenges AIG faces in improving operating performance, S&amp;P doesn't expect to be boosting its rating in the next 24 months.</li></ul><div class=\"tiny-share-widget\" data-id=\"3239171\" data-linked=\"AIG -1.1% as S&amp;P downgrades\" data-tweet=\"$AIG - AIG -1.1% as S&amp;P downgrades https://seekingalpha.com/news/3239171-aigminus-1_1-s-and-p-downgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3239171-aigminus-1_1-s-and-p-downgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239165\" data-ts=\"1485880043\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239165-analysts-weigh-in-on-tevas-loss-in-copaxone-patent-case\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts weigh in on Teva&#39;s loss in Copaxone patent case</a></h4><ul><li>Teva Pharmaceutical Industries' (<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='red'>-3.3%</font>) failure to successfully defend its Copaxone patents bodes well for the generic firms vying for a slice of its $4B business.</li><li>BOFML: The ruling was not surprising and Teva risk/reward more appealing now. Upgrades to Buy with a $42 (26% upside) price target since generic entry in Q1 already baked into to price.</li><li>Stifel: Expects lone remaining Copaxone patent to be invalidated, likely Q1 entry for generic.</li><li>Credit Suisse: Expects to Teva to seek preliminary injunction against generic launches pending appeal. Rates the stock Outperform.</li><li>Oppenheimer: Sell-off is a worse-case scenario. Teva's $1B - 2B revenue cut on Copaxone U.S. sales may be conservative if NVS/MNTA generic is the only approved this year or if approval occurs after February. Rates Teva Outperform.</li><li>Cowen: Teva should immediately take aggressive measures to control spending. Rates the stock a Buy based on valuation.</li><li>Source: Bloomberg</li><li>Related tickers: (<a href='https://seekingalpha.com/symbol/MNTA' title='Momenta Pharmaceuticals, Inc.'>MNTA</a> <font color='green'>+20.5%</font>)(<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color='green'>+1.7%</font>)(<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color='green'>+2%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3239165\" data-linked=\"Analysts weigh in on Teva&#39;s loss in Copaxone patent case\" data-tweet=\"$TEVA $TEVA $MNTA - Analysts weigh in on Teva&#39;s loss in Copaxone patent case https://seekingalpha.com/news/3239165-analysts-weigh-in-on-tevas-loss-in-copaxone-patent-case?source=tweet\" data-url=\"https://seekingalpha.com/news/3239165-analysts-weigh-in-on-tevas-loss-in-copaxone-patent-case\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239164\" data-ts=\"1485879255\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRYS\" target=\"_blank\">DRYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239164-dryships-updates-on-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DryShips updates on stock offering</a></h4><ul> <li>DryShips (<a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='green'>+81.3%</font>)&nbsp;announces that it completed the previously announced $200M common stock offering.</li><li>The company raised net proceeds of $198M.</li><li>It's somewhat hard to keep track of amid the reverse splits, but the company now has approximately 36.253M shares outstanding.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16728230-dryships-inc-announces-successful-completion-200_0-million-common-stock-offering\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3239164\" data-linked=\"DryShips updates on stock offering\" data-tweet=\"$DRYS - DryShips updates on stock offering https://seekingalpha.com/news/3239164-dryships-updates-on-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3239164-dryships-updates-on-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239159\" data-ts=\"1485878473\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDTI\" target=\"_blank\">IDTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239159-needham-company-reissues-integrated-device-technology-buy-increases-to-28-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Needham &amp; Company reissues Integrated Device Technology at Buy, increases to $28 target</a></h4><ul><li>Integrated Device Technology's (<a href='https://seekingalpha.com/symbol/IDTI' title='Integrated Device Technology, Inc.'>IDTI</a> <font color='red'>-5.2%</font>) Q4 2017 revenue guidance is at issue following&nbsp;<a href=\"https://seekingalpha.com/news/3238907-integrated-device-technology-minus-4_16-percent-q3-2017-okay-q4-forecast-light\" target=\"_blank\">Q3 2017 reporting</a>, with the light forecast attributed to a <a href=\"https://seekingalpha.com/article/4040834-integrated-device-technology-idti-q3-2017-results-earnings-call-transcript?part=single\" target=\"_blank\">pushed-out launch</a> at a major handset customer (likely Samsung Galaxy S8). Management, however, remains highly confident positioning to that end is secure.</li><li><a href=\"http://www.streetinsider.com/Analyst+Comments/Integrated+Device+Technology+%28IDTI%29%3A+Weakness+Is+Temporary+-+Needham/12477715.html\" target=\"_blank\">Analyst Quinn Bolton</a>, despite the near-term delay, notes sensor business strength with multiple Tier-1 design wins, an expected memory interface revenue rebound and disciplined operating expense control in bullish coverage.</li><li>Price target from $25 prior.</li></ul><div class=\"tiny-share-widget\" data-id=\"3239159\" data-linked=\"Needham &amp; Company reissues Integrated Device Technology at Buy, increases to $28 target\" data-tweet=\"$IDTI - Needham &amp; Company reissues Integrated Device Technology at Buy, increases to $28 target https://seekingalpha.com/news/3239159-needham-company-reissues-integrated-device-technology-buy-increases-to-28-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3239159-needham-company-reissues-integrated-device-technology-buy-increases-to-28-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239124\" data-ts=\"1485878423\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239124-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/MNTA' title='Momenta Pharmaceuticals, Inc.'>MNTA</a> <font color='green'>+20%</font>. SSH <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/MDWD' title='Mediwound Ltd.'>MDWD</a> <font color='green'>+9%</font>. APRI <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TENX' title='Tenax Therapeutics, Inc.'>TENX</a> <font color='red'>-76%</font>. <a href='https://seekingalpha.com/symbol/DMTX' title='Dimension Therapeutics'>DMTX</a> <font color='red'>-48%</font>. <a href='https://seekingalpha.com/symbol/PMD' title='Psychemedics Corporation'>PMD</a> <font color='red'>-36%</font>. <a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/NOVN' title='Novan'>NOVN</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3239124\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$AEZS $MNTA $CHFS - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3239124-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3239124-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239158\" data-ts=\"1485878420\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDX\" target=\"_blank\">FDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239158-fedex-follows-ups-lower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FedEx follows UPS lower</a></h4><ul> <li>FedEx (NYSE:<a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a>) is <font color='red'>down 2.81%</font> after guidance from rival UPS rattles investors.</li> <li>A common theme across both companies is how they manage the extra costs from the e-commerce boom and the impact on margins on shifts in mix.</li><li>The UPS conference call delved into President Trump's trade policies. Management kept it simple by saying the company supports free trade whether via bilateral deals or through broader agreements.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3239014-united-parcel-service-misses-0_06-misses-revenue\" target=\"_blank\">United Parcel Service misses by $0.06, misses on revenue</a> (Jan. 31)</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3239038-weak-guidance-earnings-miss-sends-ups-lower\" target=\"_blank\">Weak guidance and earnings miss sends UPS lower</a> (Jan. 31)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3239158\" data-linked=\"FedEx follows UPS lower\" data-tweet=\"$FDX - FedEx follows UPS lower https://seekingalpha.com/news/3239158-fedex-follows-ups-lower?source=tweet\" data-url=\"https://seekingalpha.com/news/3239158-fedex-follows-ups-lower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239155\" data-ts=\"1485877902\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FNBC\" target=\"_blank\">FNBC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239155-first-nbc-plunges-25-on-dta-impairment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">First NBC plunges 25% on DTA impairment</a></h4><ul><li>It's another big leg down for the troubled Louisiana lender after saying it expects to have to book a material valuation allowance on its DTA in Q4. The company at this time is unable to estimate the amount.</li><li><a href=\"https://seekingalpha.com/filing/3376828\" target=\"_blank\">SEC Form 8-K</a></li><li><a href='https://seekingalpha.com/symbol/FNBC' title='First NBC Bank Holding Company'>OTC:FNBC</a>&nbsp;<font color='red'>-25.2%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3239155\" data-linked=\"First NBC plunges 25% on DTA impairment\" data-tweet=\"$FNBC - First NBC plunges 25% on DTA impairment https://seekingalpha.com/news/3239155-first-nbc-plunges-25-on-dta-impairment?source=tweet\" data-url=\"https://seekingalpha.com/news/3239155-first-nbc-plunges-25-on-dta-impairment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>101&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239149\" data-ts=\"1485877302\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AEZS\" target=\"_blank\">AEZS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239149-aeterna-completes-late-stage-study-of-zoptrex-in-endometrial-cancer-top-line-data-expected-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aeterna completes late-stage study of Zoptrex in endometrial cancer, top-line data expected in April, shares ahead 23%</a></h4><ul><li>Thinly traded nano cap Aeterna Zentaris (<a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a> <font color='green'>+23.1%</font>) reaches the <a href=\"https://seekingalpha.com/pr/16727374-aeterna-zentaris-announces-completion-zoptrex-pivotal-phase-3-clinical-trial-advanced\" target=\"_blank\">clinical endpoint</a> in its Phase 3 study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT01767155?term=zoptarelin&amp;phase=2&amp;rank=1\" target=\"_blank\">ZoptEC</a>, assessing Zoptrex (zoptarelin doxorubicin) in women with treatment-resistant advanced endometrial cancer. Data lock and the release of top-line results should happen in April. Enrollment was completed in June 2015 and the final dosing was completed in January 2016.</li><li>The primary endpoint is overall survival compared to doxorubicin alone.</li><li><a href=\"http://aezsinc.com/portfolio/r-d-programs/zoptarelin-doxorubicin-endometrial\" target=\"_blank\">Zoptrex&nbsp;</a>combines a synthetic peptide carrier with the chemo agent doxorubicin. The carrier, a modified natural hormone with a strong affinity for the LHRH (luteinizing hormone-releasing hormone) receptor, enables the selective delivery of the chemo agent to LHRH receptor-positive tumors.</li></ul><div class=\"tiny-share-widget\" data-id=\"3239149\" data-linked=\"Aeterna completes late-stage study of Zoptrex in endometrial cancer, top-line data expected in April, shares ahead 23%\" data-tweet=\"$AEZS - Aeterna completes late-stage study of Zoptrex in endometrial cancer, top-line data expected in April, shares ahead 23% https://seekingalpha.com/news/3239149-aeterna-completes-late-stage-study-of-zoptrex-in-endometrial-cancer-top-line-data-expected-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3239149-aeterna-completes-late-stage-study-of-zoptrex-in-endometrial-cancer-top-line-data-expected-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239160\" data-ts=\"1485877021\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NGD\" target=\"_blank\">NGD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239160-analysts-slam-new-gold-for-rainy-river-delay\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts slam New Gold for Rainy River delay</a></h4><ul><li>New Gold (<a href='https://seekingalpha.com/symbol/NGD' title='New Gold Inc'>NGD</a> <font color='red'>-10.5%</font>) plunges for a second straight day, with its market cap slashed by a third, after it <a href=\"https://seekingalpha.com/news/3238662-new-gold-promotes-portmann-ceo-says-2016-gold-output-hits-381k-oz\" target=\"_blank\">selected a new CEO</a> and announced a three-month delay to its Rainy River startup mine in Canada due to a slower than planned ramp-up of mining rates impacting delivery of construction materials.</li><li>NGD also warned that 2017 capex is expected to come in $195M higher than previously expected.</li><li>BMO <a href=\"http://business.financialpost.com/investing/trading-desk/new-golds-target-price-cut-on-rainy-river-delay\" target=\"_blank\">cuts its NGD price target to C$4.50</a> from C$5.25  &ldquo;given the delays/capital overruns and the resulting funding gap,\" and GMP&nbsp;Securities <a href=\"http://www.streetinsider.com/Analyst+Comments/GMP+Securities+Downgrades+New+Gold+%28NGD%29+to+Hold/12477774.html\" target=\"_blank\">downgrades</a> shares to Hold from Buy with a C$4.80 price target.</li></ul><div class=\"tiny-share-widget\" data-id=\"3239160\" data-linked=\"Analysts slam New Gold for Rainy River delay\" data-tweet=\"$NGD - Analysts slam New Gold for Rainy River delay https://seekingalpha.com/news/3239160-analysts-slam-new-gold-for-rainy-river-delay?source=tweet\" data-url=\"https://seekingalpha.com/news/3239160-analysts-slam-new-gold-for-rainy-river-delay\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239146\" data-ts=\"1485876935\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CELG\" target=\"_blank\">CELG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239146-biotechs-up-nearly-2-trump-promises-faster-acting-fda\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biotechs up nearly 2% as Trump promises faster-acting FDA</a></h4><ul><li>The broad averages are in the red, but the iShares Biotech ETF (<a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a> <font color='green'>+1.8%</font>) is surging as<a href=\"https://seekingalpha.com/news/3239123-president-trump-encouraging-news-drug-makers-criticism-high-prices-remains\" target=\"_blank\"> the president meets</a> with pharma company executives.</li><li>While the meeting included familiar D.C. carping about drug prices, the president also promised to soon announce a new FDA leader whose mission, in part, will be to speed the drug approval process.</li><li>The president, naturally, is also urging the \"onshoring\" of drug manufacturing.</li><li>Other pharma/healthcare ETFs: &nbsp;<a href='https://seekingalpha.com/symbol/PJP' title='Invesco Dynamic Pharmaceuticals Portfolio ETF'>PJP</a>&nbsp;<font color='green'>+1.35%</font>, <a href='https://seekingalpha.com/symbol/XPH' title='SPDR S&P Pharmaceuticals ETF'>XPH</a>&nbsp;<font color='green'>+1.8%</font>, <a href='https://seekingalpha.com/symbol/XLV' title='Health Care Select Sect SPDR ETF'>XLV</a>&nbsp;<font color='green'>+0.85%</font></li><li>Among the meeting attendees: Celgene (<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a> <font color='green'>+1.9%</font>), Amgen (<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color='green'>+1%</font>), Eli Lilly (<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a> <font color='green'>+1.7%</font>).</li><li>ETFs: <a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a>, <a href='https://seekingalpha.com/symbol/XLV' title='Health Care Select Sect SPDR ETF'>XLV</a>, <a href='https://seekingalpha.com/symbol/IYH' title='iShares U.S. Healthcare ETF'>IYH</a>, <a href='https://seekingalpha.com/symbol/XBI' title='SPDR Biotech ETF'>XBI</a>, <a href='https://seekingalpha.com/symbol/VHT' title='Vanguard Health Care ETF'>VHT</a>, <a href='https://seekingalpha.com/symbol/PJP' title='Invesco Dynamic Pharmaceuticals Portfolio ETF'>PJP</a>, <a href='https://seekingalpha.com/symbol/BBH' title='VanEck Vectors Biotech ETF'>BBH</a>, <a href='https://seekingalpha.com/symbol/HQH' title='Tekla Healthcare Investors'>HQH</a>, <a href='https://seekingalpha.com/symbol/FBT' title='First Trust NYSE Arca Biotechnology Index ETF'>FBT</a>, <a href='https://seekingalpha.com/symbol/CURE' title='Direxion Daily Healthcare Bull 3x Shares ETF'>CURE</a>, <a href='https://seekingalpha.com/symbol/HQL' title='Tekla Life Sciences Investors'>HQL</a>, <a href='https://seekingalpha.com/symbol/XPH' title='SPDR S&P Pharmaceuticals ETF'>XPH</a>, <a href='https://seekingalpha.com/symbol/PBE' title='Invesco Dynamic Biotechnology & Genome Portfolio ETF'>PBE</a>, <a href='https://seekingalpha.com/symbol/FXH' title='First Trust Health Care AlphaDEX ETF'>FXH</a>, <a href='https://seekingalpha.com/symbol/FHLC' title='Fidelity MSCI Health Care Index ETF'>FHLC</a>, <a href='https://seekingalpha.com/symbol/IHE' title='iShares U.S. Pharmaceuticals ETF'>IHE</a>, <a href='https://seekingalpha.com/symbol/RXL' title='ProShares Ultra Health Care ETF'>RXL</a>, <a href='https://seekingalpha.com/symbol/LABU' title='Direxion Daily S&P Biotech Bull 3x Shares ETF'>LABU</a>, <a href='https://seekingalpha.com/symbol/BBC' title='BioShares Biotechnology Clinical Trials ETF'>BBC</a>, <a href='https://seekingalpha.com/symbol/PPH' title='VanEck Vectors Pharmaceutical ETF'>PPH</a>, <a href='https://seekingalpha.com/symbol/THQ' title='Tekla Healthcare Opportunities Fund'>THQ</a>, <a href='https://seekingalpha.com/symbol/RYH' title='Invesco S&P Equal Weight Health Care ETF'>RYH</a>, <a href='https://seekingalpha.com/symbol/BBP' title='BioShares Biotechnology Products ETF'>BBP</a>, <a href='https://seekingalpha.com/symbol/LABD' title='Direxion Daily S&P Biotech Bear 3x Shares ETF'>LABD</a>, <a href='https://seekingalpha.com/symbol/UBIO' title='ProShares UltraPro NASDAQ Biotechnology ETF'>UBIO</a>, <a href='https://seekingalpha.com/symbol/ZBIO' title='ProShares UltraPro Short NASDAQ Biotechnology ETF'>ZBIO</a>, <a href='https://seekingalpha.com/symbol/RXD' title='ProShares UltraShort Health Care ETF'>RXD</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3239146\" data-linked=\"Biotechs up nearly 2% as Trump promises faster-acting FDA\" data-tweet=\"$CELG $IBB $PJP - Biotechs up nearly 2% as Trump promises faster-acting FDA https://seekingalpha.com/news/3239146-biotechs-up-nearly-2-trump-promises-faster-acting-fda?source=tweet\" data-url=\"https://seekingalpha.com/news/3239146-biotechs-up-nearly-2-trump-promises-faster-acting-fda\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>195&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239141\" data-ts=\"1485876547\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STRP\" target=\"_blank\">STRP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239141-straight-pathplus-11_2-in-face-of-new-kerrisdale-spectrum-thesis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Straight Path +11.2% in face of new Kerrisdale spectrum thesis</a></h4><ul>   <li>Straight Path Communications (NYSEMKT:<a href='https://seekingalpha.com/symbol/STRP' title='Straight Path Communications Inc.'>STRP</a>) is <font color='green'>up 11.2%</font> and recovering Friday's levels, even as notable company short seller Kerrisdale Capital <a href=\"https://seekingalpha.com/article/4040952-straight-path-communications-critical-look-5g\" target=\"_blank\">presses its case</a> saying that if 5G skeptics are right, the company's spectrum has \"almost no value.\"</li>    <li>Even if carriers commit to millimeter wave 5G, the company is highly overvalued, Kerrisdale argues. But millimeter wave may be too expensive to deploy for services that won't draw higher payments from customers.</li>    <li>\"The high costs and unclear benefits of mmWave 5G will translate to slow, patchy deployments at best, tightly circumscribing Straight Path's value,\" the firm argues.</li>    <li>For Straight Path, AT&amp;T and T-Mobile are the only realistic buyers for the bulk of its spectrum, Kerrisdale argues, but their motives would be to provide millimeter wave mobile service. \"With large mmWave auctions on the horizon and additional bands in the pipeline, there's no reason to pay up for Straight Path.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3239141\" data-linked=\"Straight Path +11.2% in face of new Kerrisdale spectrum thesis\" data-tweet=\"$STRP - Straight Path +11.2% in face of new Kerrisdale spectrum thesis https://seekingalpha.com/news/3239141-straight-pathplus-11_2-in-face-of-new-kerrisdale-spectrum-thesis?source=tweet\" data-url=\"https://seekingalpha.com/news/3239141-straight-pathplus-11_2-in-face-of-new-kerrisdale-spectrum-thesis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239138\" data-ts=\"1485876332\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CIT\" target=\"_blank\">CIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239138-cit-groupminus-1_65-after-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CIT Group -1.65% after Q4 results</a></h4><ul><li>Q4 income from continuing operations ex-items of $120M or $0.59 per share vs. expectations for $0.76.</li><li>Full-year income from continuing operations ex items of $368M or $1.82 per share.</li><li>End-of-year tangible book value per share of $45.41 vs. $48.50 a year earlier, and current price of $41.15. CET1 ratio of 13.8% up 110 bps.</li><li>CEO Ellen Alemany notes recent strategic actions \"significantly affected\" the quarter, and says the company has achieved one-third of its opex reduction goal.</li><li><a href=\"https://seekingalpha.com/filing/3376717\" target=\"_blank\">Earnings filing</a></li><li><a href='https://seekingalpha.com/symbol/CIT' title='CIT Group Inc.'>CIT</a>&nbsp;<font color='red'>-1.65%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3239138\" data-linked=\"CIT Group -1.65% after Q4 results\" data-tweet=\"$CIT - CIT Group -1.65% after Q4 results https://seekingalpha.com/news/3239138-cit-groupminus-1_65-after-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3239138-cit-groupminus-1_65-after-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239134\" data-ts=\"1485875680\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NUE\" target=\"_blank\">NUE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239134-nucorminus-4-on-q4-earnings-offers-positive-q1-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nucor -4% on Q4 earnings but offers positive Q1 outlook</a></h4><ul>     <li>Nucor (<a href='https://seekingalpha.com/symbol/NUE' title='Nucor Corporation'>NUE</a> <font color='red'>-3.9%</font>) opens sharply lower despite reporting better than expected <a href=\"https://seekingalpha.com/news/3239088-nucor-eps-0_50\" target=\"_blank\">Q4 earnings</a> and a 14.5% rise in revenue to $3.96B, as its steel mill shipments increased.</li><li>However, NUE's Q4 EPS of $0.50 may have included items that  were not included in the company's prior guidance of $0.30-$0.35, such as the  effects of a change in estimates related to the cost of certain  inventories, which resulted in a $0.16 benefit.</li><li>Q4 operating rates at NUE's steel mills slipped to 74% vs. 76% in Q3 but rose from 68% in Q4 2015; steel  mill operating rates for full-year 2016 increased to 80% from 73% a year earlier.</li><li>NUE says profitability for its steel products segment fell Q/Q due to end-of-year seasonality, but it expects earnings to rise  in Q1 and believes FY 2017 profitability could significantly exceed 2016 levels; prices  began to rise in Q4 for its steel mills segment, and NUE expects  the trend will continue into Q1.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3239134\" data-linked=\"Nucor -4% on Q4 earnings but offers positive Q1 outlook\" data-tweet=\"$NUE - Nucor -4% on Q4 earnings but offers positive Q1 outlook https://seekingalpha.com/news/3239134-nucorminus-4-on-q4-earnings-offers-positive-q1-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3239134-nucorminus-4-on-q4-earnings-offers-positive-q1-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239133\" data-ts=\"1485875661\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XRX\" target=\"_blank\">XRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239133-on-xeroxs-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Xerox&#39;s Q4</a></h4><ul>     <li>Xerox (<a href='https://seekingalpha.com/symbol/XRX' title='Xerox Corporation'>XRX</a> <font color='red'>-4%</font>)&nbsp;reports revenue declined 5% on an&nbsp;adjusted&nbsp;constant currency basis in <a href=\"https://seekingalpha.com/pr/16727634-xerox-reports-fourth-quarter-2016-earnings\" target=\"_blank\">Q4</a>.</li>     <li>Services revenue decreased 4% to $894M (flat in constant currency).</li>     <li>Document technology revenue fell 10% to $1.69B (-8% in constant currency).</li>     <li>Equipment sales down 12% to $677M&nbsp;(-10% in constant currency).</li>     <li>Annuity revenue squeezed 5% to $2.06B&nbsp;(-3% in constant currency).</li>     <li>Adjusted gross margin rate +10 bps to 40.3%.</li>     <li>Adjusted SG&amp;A expense rate improved 60 bps 23.1%.</li>     <li>Operating margin rate up 70 bps to 14%.</li>     <li><b>FY2017 Guidance</b>: Diluted EPS: $0.44 to $0.52; Adjusted EPS: $0.80 to $0.88; Cash flow from operations: $700M to $900M; Free cash flow: $525M to $725M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3239133\" data-linked=\"More on Xerox&#39;s Q4\" data-tweet=\"$XRX - More on Xerox&#39;s Q4 https://seekingalpha.com/news/3239133-on-xeroxs-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3239133-on-xeroxs-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239131\" data-ts=\"1485875539\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTSH\" target=\"_blank\">CTSH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239131-cognizant-technology-solutions-downgraded-to-equal-weight-morgan-stanley\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cognizant Technology Solutions downgraded to Equal Weight at Morgan Stanley</a></h4><ul><li>From Overweight, <a href=\"http://www.streetinsider.com/Analyst+Comments/Morgan+Stanley+Downgrades+Cognizant+Technology+Solutions+%28CTSH%29+to+Equalweight/12476823.html\" target=\"_blank\">analyst Brian Essex</a> notes a decent recovery from lows during fall 2016 and ongoing exposure to multiple catalysts with the potential to generate growth above discouraging levels in the prior year. However, factors heightened risk involving tax reform and headline risk of <a href=\"https://seekingalpha.com/news/3238741-bloomberg-executive-order-draft-proposal-targets-overhaul-work-visa-programs\" target=\"_blank\">visa-related developments</a> expected to persist through 2017 in sidelining coverage.</li><li>Cognizant Technology Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/CTSH' title='Cognizant Technology Solutions Corporation'>CTSH</a>) price target to $59 from $61 (current price $52.46,&nbsp;<font color='red'>-2.24%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3239131\" data-linked=\"Cognizant Technology Solutions downgraded to Equal Weight at Morgan Stanley\" data-tweet=\"$CTSH - Cognizant Technology Solutions downgraded to Equal Weight at Morgan Stanley https://seekingalpha.com/news/3239131-cognizant-technology-solutions-downgraded-to-equal-weight-morgan-stanley?source=tweet\" data-url=\"https://seekingalpha.com/news/3239131-cognizant-technology-solutions-downgraded-to-equal-weight-morgan-stanley\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239130\" data-ts=\"1485875054\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COLM\" target=\"_blank\">COLM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239130-under-armour-earnings-misfire-creates-shockwave-of-anxiety\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Under Armour earnings misfire creates shockwave of anxiety</a></h4><ul> <li>An earnings misfire from Under Armour is causing anxiety across a wide cross-section of the apparel sector. The general sentiment is that if a high-energy growth company like Under Armour was whacked by the macro environment, then a reset on expectations may be warranted.</li> <li>Decliners in early trading include Columbia Sportswear (<a href='https://seekingalpha.com/symbol/COLM' title='Columbia Sportswear Company'>COLM</a> <font color='red'>-2.1%</font>), Sequential Brands Group (<a href='https://seekingalpha.com/symbol/SQBG' title='Sequential Brands Group, Inc.'>SQBG</a> <font color='red'>-2.4%</font>), G-III Apparel (<a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, LTD.'>GIII</a> <font color='red'>-3.5%</font>), Big Five Sporting Goods (<a href='https://seekingalpha.com/symbol/BGFV' title='Big 5 Sporting Goods Corporation'>BGFV</a> <font color='red'>-1.9%</font>), Hibbett Sports (<a href='https://seekingalpha.com/symbol/HIBB' title='Hibbett Sports, Inc.'>HIBB</a> <font color='red'>-2.2%</font>), VF Corp (<a href='https://seekingalpha.com/symbol/VFC' title='V.F. Corporation'>VFC</a> <font color='red'>-2.6%</font>), Wolverine Worldwide (<a href='https://seekingalpha.com/symbol/WWW' title='Wolverine World Wide Inc.'>WWW</a> <font color='red'>-1.3%</font>), Crocs (<a href='https://seekingalpha.com/symbol/CROX' title='Crocs, Inc.'>CROX</a> <font color='red'>-2.1%</font>), Skechers (<a href='https://seekingalpha.com/symbol/SKX' title='Skechers USA Inc.'>SKX</a> <font color='red'>-2.1%</font>), Gap (<a href='https://seekingalpha.com/symbol/GPS' title='The Gap, Inc.'>GPS</a> <font color='red'>-2.6%</font>), Macy's (<a href='https://seekingalpha.com/symbol/M' title='Macy&#39;s Inc.'>M</a> <font color='red'>-2.2%</font>), Finish Line (<a href='https://seekingalpha.com/symbol/FINL' title='The Finish Line, Inc.'>FINL</a> <font color='red'>-0.5%</font>), Hanesbrands (<a href='https://seekingalpha.com/symbol/HBI' title='Hanesbrands Inc.'>HBI</a> <font color='red'>-1.9%</font>), Dick's Sporting Goods (<a href='https://seekingalpha.com/symbol/DKS' title='Dick&#39;s Sporting Goods, Inc.'>DKS</a> <font color='red'>-3.4%</font>), Genesco (<a href='https://seekingalpha.com/symbol/GCO' title='Genesco Inc.'>GCO</a> <font color='red'>-1.8%</font>) and Ascena Retail (<a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group Inc'>ASNA</a> <font color='red'>-2%</font>).</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3239118-armour-punished-flat-footed-performance\" target=\"_blank\">Under Armour punished after flat-footed performance</a> (Jan. 31)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3239130\" data-linked=\"Under Armour earnings misfire creates shockwave of anxiety\" data-tweet=\"$COLM $COLM $SQBG - Under Armour earnings misfire creates shockwave of anxiety https://seekingalpha.com/news/3239130-under-armour-earnings-misfire-creates-shockwave-of-anxiety?source=tweet\" data-url=\"https://seekingalpha.com/news/3239130-under-armour-earnings-misfire-creates-shockwave-of-anxiety\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239123\" data-ts=\"1485874488\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239123-president-trump-encouraging-news-for-drug-makers-criticism-of-high-prices-remains\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">President Trump has some encouraging news for drug makers, but criticism of high prices remains</a></h4><ul><li>The market's red territory notwithstanding, drug and biotech stocks are under pressure again stemming from President Trump's continued criticism over high prices, called them \"astronomical.\"</li><li>In a meeting with industry leaders Mr. Trump was generally upbeat, saying he favors a much faster FDA approval process and easier access to new drugs for terminal patients. He added that regulations \"will be cut to a level never seen before\" and committed to \"end the freeloading on foreign price controls.\"</li><li>Source: Bloomberg</li><li>ETFs: <a href='https://seekingalpha.com/symbol/BIB' title='ProShares Ultra Nasdaq Biotechnology ETF'>BIB</a>, <a href='https://seekingalpha.com/symbol/GRX' title='The Gabelli Healthcare & Wellness Rx Trust'>GRX</a>, <a href='https://seekingalpha.com/symbol/BIS' title='ProShares UltraShort Nasdaq Biotechnology ETF'>BIS</a>, <a href='https://seekingalpha.com/symbol/IRY' title='SPDR S&P International Health Care Sector ETF'>IRY</a>, <a href='https://seekingalpha.com/symbol/IXJ' title='iShares Global Healthcare ETF'>IXJ</a>, <a href='https://seekingalpha.com/symbol/BME' title='BlackRock Health Sciences Trust'>BME</a>, <a href='https://seekingalpha.com/symbol/CNCR' title='Loncar Cancer Immunotherapy ETF'>CNCR</a>, <a href='https://seekingalpha.com/symbol/THW' title='Tekla World Healthcare Fund'>THW</a>, <a href='https://seekingalpha.com/symbol/ARKG' title='ARK Genomic Revolution Multi-Sector ETF'>ARKG</a>, <a href='https://seekingalpha.com/symbol/GNRX' title='VanEck Vectors Generic Drugs ETF'>GNRX</a>, <a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3239123\" data-linked=\"President Trump has some encouraging news for drug makers, but criticism of high prices remains\" data-tweet=\"$BIB $GRX $BIS - President Trump has some encouraging news for drug makers, but criticism of high prices remains https://seekingalpha.com/news/3239123-president-trump-encouraging-news-for-drug-makers-criticism-of-high-prices-remains?source=tweet\" data-url=\"https://seekingalpha.com/news/3239123-president-trump-encouraging-news-for-drug-makers-criticism-of-high-prices-remains\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239122\" data-ts=\"1485874330\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239122-dollar-gives-up-post-election-gains\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dollar gives up more post-election gains</a></h4><ul><li><font color='red'>Down another 0.7%</font>&nbsp;this morning, the dollar index <a href=\"http://finviz.com/futures_charts.ashx?p=d1&amp;t=DX\" target=\"_blank\">has returned to levels</a> last seen in early December, and is within sight of pre-election levels.</li><li><a href=\"https://dagzy8uu071gh.cloudfront.net/Currency%20Weekly%20%281%29.pdf\" target=\"_blank\">In a note titled,</a> \"Trump, the currency manipulator,\" HSBC says the president's rhetoric has been a key factor behind the decline. Trump's hope for a weaker dollar, however, is likely to be undone by his policy mix, which the HSBC team sees as mostly dollar-positive.</li><li>Among those are tax cuts and a federal spending surge - policies that typically cause the dollar to rise. Trump also wants to encourage domestic investment and discourage capital from exiting - again dollar positive. There's also immigration limits which imply a tighter jobs market, and thus a tighter Fed - dollar positive.</li><li>In currency markets, talk can cause short-term moves, but it's ultimately cheap if not accompanied by complementary policy action.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/UUP' title='PowerShares DB USD Bull ETF'>UUP</a>, <a href='https://seekingalpha.com/symbol/UDN' title='PowerShares DB USD Bear ETF'>UDN</a>, <a href='https://seekingalpha.com/symbol/USDU' title='WisdomTree Bloomberg U.S. Dollar Bullish ETF'>USDU</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3239122\" data-linked=\"Dollar gives up more post-election gains\" data-tweet=\"$UUP $UDN $USDU - Dollar gives up more post-election gains https://seekingalpha.com/news/3239122-dollar-gives-up-post-election-gains?source=tweet\" data-url=\"https://seekingalpha.com/news/3239122-dollar-gives-up-post-election-gains\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239120\" data-ts=\"1485874255\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLYS\" target=\"_blank\">TLYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239120-tillys-announces-special-dividend-updates-on-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tilly&#39;s announces special dividend, updates on Q4 results</a></h4><ul> <li>Tilly&rsquo;s (<a href='https://seekingalpha.com/symbol/TLYS' title='Tilly&#39;s, Inc.'>TLYS</a> <font color='green'>+4.5%</font>)&nbsp;announced a special cash dividend of $0.70 per share on the company&rsquo;s Class A and       Class B stock.</li>     <li>The one-time special dividend is payable on       February 24.</li>     <li>The company also updates on results. Comparable store sales increased 0.1% in Q4. Tilly's now expects EPS to be in the range of $0.21 to $0.22 for the quarter.</li><li>&ldquo;The improvement in our fourth quarter outlook reflects better       than anticipated product margins and expenses on same-store sales that       were within our original outlook range,\" says CEO Ed Thomas.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16727651-tilly-s-inc-declares-special-dividend-0_70-per-share\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3239120\" data-linked=\"Tilly&#39;s announces special dividend, updates on Q4 results\" data-tweet=\"$TLYS - Tilly&#39;s announces special dividend, updates on Q4 results https://seekingalpha.com/news/3239120-tillys-announces-special-dividend-updates-on-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3239120-tillys-announces-special-dividend-updates-on-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239118\" data-ts=\"1485873966\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UA\" target=\"_blank\">UA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239118-under-armour-punished-after-flat-footed-performance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Under Armour punished after flat-footed performance</a></h4><ul> <li>Guidance from Under Armour (<a href='https://seekingalpha.com/symbol/UA' title='Under Armour, Inc. Class C'>UA</a>, <a href='https://seekingalpha.com/symbol/UAA' title='Under Armour, Inc.'>UAA</a>) that falls well below estimates is sending investors scrambling.</li> <li>The company expects Q1 revenue to increase at a mid single-digit rate vs. +23% consensus estimate.</li> <li>An operating loss of $12M to $14M is cited on the conference call.</li> <li>Competitive pressures and inventory management issues seemed to have caught the company off-guard, while F/X cut into revenue more than anticipated and a shift in sales mix (higher international vs. U.S.) hurt margins.</li> <li>Shares of Under Armour are <font color='red'>down 24.99%</font> and traded as low as $18.52 vs. a 52-week high of $46.20.</li><li>Sources: UA conference call webcast and CNBC.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3238994-armour-minus-17-percent-results-disappoint\" target=\"_blank\">Under Armour -17% after results disappoint</a> (Jan. 31)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3238997-armour-cfo-resigns\" target=\"_blank\">Under Armour CFO resigns</a> (Jan. 31)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3239118\" data-linked=\"Under Armour punished after flat-footed performance\" data-tweet=\"$UA $UA $UAA - Under Armour punished after flat-footed performance https://seekingalpha.com/news/3239118-under-armour-punished-after-flat-footed-performance?source=tweet\" data-url=\"https://seekingalpha.com/news/3239118-under-armour-punished-after-flat-footed-performance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>65&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239116\" data-ts=\"1485873666\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDWD\" target=\"_blank\">MDWD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239116-mediwounds-escharex-successful-in-mid-stage-study-shares-ease-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MediWound&#39;s EscharEx successful in mid-stage study, shares ease 1%</a></h4><ul><li>Thinly traded micro cap MediWound (<a href='https://seekingalpha.com/symbol/MDWD' title='Mediwound Ltd.'>MDWD</a>) can't fight off the market's foul mood in early trading despite <a href=\"https://seekingalpha.com/pr/16727682-mediwound-reports-final-positive-results-phase-2-clinical-trial-escharex-debridement-chronic\" target=\"_blank\">positive final results</a> from a Phase 2 study assessing the effect of EscharEx in treating hard-to-heal wounds (results were first reported a year ago).</li><li>EscharEx is biopharmaceutical based on the same proteolytic enzyme technology used in the company's&nbsp;<a href=\"http://www.mediwound.com/products/nexobrid/\" target=\"_blank\">NexoBrid&nbsp;</a>product which is commercially available in Europe and Israel for the removal of&nbsp;<a href=\"https://en.wikipedia.org/wiki/Eschar\" target=\"_blank\">eschar&nbsp;</a>(dead skin) in adults with serious thermal burns.</li><li>The 73-subject trial compared EscharEx to hydrogel vehicle in treatment-resistant wounds, including diabetic foot ulcers, venous leg ulcers and post-surgical and traumatic wounds. The primary endpoint was the incidence of completed debridement (removal of non-viable tissue) at the end of the debridement period (up to 10 treatment days).</li><li>Patients treated with EscharEx experienced a higher incidence of complete debridement (55%) compared to hydrogel vehicle (29%) (p=0.047). The difference was more profound in patients with diabetic foot ulcers and venous leg ulcers.</li><li>The company intends to share the data with the FDA and expects to advance EscharEx into Phase 3 development.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3077856-mediwounds-escharex-successful-mid-stage-study-shares-13-percent\" target=\"_blank\">MediWound's EscharEx successful in mid-stage study; shares up 13%</a> (Feb. 3, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3239116\" data-linked=\"MediWound&#39;s EscharEx successful in mid-stage study, shares ease 1%\" data-tweet=\"$MDWD - MediWound&#39;s EscharEx successful in mid-stage study, shares ease 1% https://seekingalpha.com/news/3239116-mediwounds-escharex-successful-in-mid-stage-study-shares-ease-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3239116-mediwounds-escharex-successful-in-mid-stage-study-shares-ease-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239111\" data-ts=\"1485873188\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMTC\" target=\"_blank\">BMTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239111-bryn-mawr-trust-to-buy-royal-bancshares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bryn Mawr Trust to buy Royal Bancshares</a></h4><ul><li>There's some M&amp;A activity in the Philadelphia suburbs this morning, with Bryn Mawr Bank (NASDAQ:<a href='https://seekingalpha.com/symbol/BMTC' title='Bryn Mawr Bank Corporation'>BMTC</a>) agreeing <a href=\"https://seekingalpha.com/pr/16728030-bryn-mawr-bank-corporation-acquire-royal-bancshares-pennsylvania-inc\" target=\"_blank\">to purchase</a> Royal Bancshares of Pennsylvania (NASDAQ:<a href='https://seekingalpha.com/symbol/RBPAA' title='Royal Bancshares of Pennsylvania, Inc.'>RBPAA</a>) in a $127.7M all-stock deal.</li><li>The acquisition will add about $602M in loans and $630M in deposits to the Bryn Mawr balance sheet.</li><li>The deal terms represent 165.9% of Royal's adjusted tangible book valuer per share and 25x adjusted 2016 net income.</li><li>The purchase is expected to immediately be accretive to BMT's tangible book value per share, and to EPS during the first year (excluding merger-related expenses).</li><li>The stock prices of both banks are modestly lower in opening action.</li></ul><div class=\"tiny-share-widget\" data-id=\"3239111\" data-linked=\"Bryn Mawr Trust to buy Royal Bancshares\" data-tweet=\"$BMTC $BMTC $RBPAA - Bryn Mawr Trust to buy Royal Bancshares https://seekingalpha.com/news/3239111-bryn-mawr-trust-to-buy-royal-bancshares?source=tweet\" data-url=\"https://seekingalpha.com/news/3239111-bryn-mawr-trust-to-buy-royal-bancshares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:33 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239104\" data-ts=\"1485872776\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/S\" target=\"_blank\">S</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239104-sprintplus-1_5-cost-trimming-boost-to-revenue-narrow-net-loss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sprint +1.5% as cost-trimming, boost to revenue narrow its net loss</a></h4><ul>   <li>Sprint (NYSE:<a href='https://seekingalpha.com/symbol/S' title='Sprint Corporation'>S</a>) is <font color='green'>up 1.5%</font> premarket just before the open, after <a href=\"https://seekingalpha.com/news/3239003-sprint-misses-0_04-beats-revenue\" target=\"_blank\">fiscal Q3 revenue</a> that grew nearly 5% easily beat expectations and the company boosted its full-year outlook, though its net loss disappointed and postpaid churn rose both sequentially and Y/Y.</li>    <li>Sprint's cut expenses by about $1.6B so far, its CFO says, while it continues to grow the top line. A change to its service and repair program earl this month is expected to be accretive to EBITDA by $25M-$50M per quarter.</li>    <li>Net income improved to -$479M from a year-ago -$836M. EBITDA came to $2.45B vs. an expected $2.34B.</li>    <li>Revenue breakout: Service, $6.32B (down 5.4%); Equipment, $2.23B (up 56.3%).</li>    <li>Total net adds came to 577,000, including 405,000 net postpaid adds, 501,000 net prepaid losses, and wholesale/affiliate net adds of 673,000. But postpaid total churn rose to 1.67%, and postpaid phone churn rose to 1.57%.</li>    <li>Total liquidity was $9.1B at quarter's end, $6.1B in cash, equivalents and short-term investments.</li>    <li>For full 2016, the company raised the low end of ranges, seeing a higher EBITDA range of $9.7B-$10B and higher operating income of $1.4B-$1.7B. Cash capex that was forecast at less than $3B is now seen at $2B-$2.3B. Meanwhile, adjusted free cash flow for the year is expected to break even.</li>    <li><a href=\"https://seekingalpha.com/pr/16727733-sprint-continues-year-year-growth-net-operating-revenues-postpaid-phone-net-additions-third\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3239104\" data-linked=\"Sprint +1.5% as cost-trimming, boost to revenue narrow its net loss\" data-tweet=\"$S - Sprint +1.5% as cost-trimming, boost to revenue narrow its net loss https://seekingalpha.com/news/3239104-sprintplus-1_5-cost-trimming-boost-to-revenue-narrow-net-loss?source=tweet\" data-url=\"https://seekingalpha.com/news/3239104-sprintplus-1_5-cost-trimming-boost-to-revenue-narrow-net-loss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239099\" data-ts=\"1485872485\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MCRB\" target=\"_blank\">MCRB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239099-seres-therapeutics-lead-product-candidate-shows-positive-effect-in-mid-stage-c-diff-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seres Therapeutics&#39; lead product candidate shows positive effect in mid-stage C. diff study; shares ahead 10% premarket</a></h4><ul><li>Thinly traded micro cap Seres Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MCRB' title='Seres Therapeutics'>MCRB</a>) perks up&nbsp;<font color='green'>10%</font>&nbsp;premarket, albeit on only 2,294 shares, in response to its <a href=\"https://www.sec.gov/Archives/edgar/data/1609809/000119312517024533/d339184dex991.htm\" target=\"_blank\">announcement </a>of positive interim results from a Phase 2 clinical trial assessing lead product candidate, Orphan Drug- and Breakthrough Therapy-tagged SER-109, for the prevention of recurrent infections due to <em>Clostridium difficile</em> (<em>C. diff</em>).</li><li>Data from the eight-week study showed a 44% (n=26/59) recurrence rate in the SER-109 group compared to a 53% (n=16/30) recurrence rate for placebo. The p value is not provided, however. On Slide #14, a relative risk &#40;RR&#41; is given (1.22) with a 95% confidence interval of 0.79 - 1.88 which implies that the treatment effect of SER-109 was not statistically significant compared to placebo (<a href=\"http://sphweb.bumc.bu.edu/otlt/mph-modules/bs/bs704_confidence_intervals/bs704_confidence_intervals8.html\" target=\"_blank\">explained here</a>).</li><li>Shares cratered in July of last year SER-109 flunked an earlier study in <em>C. diff.</em></li><li><a href=\"http://www.serestherapeutics.com/pipeline/ser-109\" target=\"_blank\">SER-109</a>&nbsp;is a single-dose capsule containing an ecology of bacterial spores enriched and purified from healthy screened human donors. Its keystone organisms address the underlying dysbiosis and returns the microbiome to a healthy state.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3197954-seres-therapeutics-minus-74-percent-lead-drug-fails-study\" target=\"_blank\">Seres Therapeutics -74% after lead drug fails in study</a> (July 29, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3239099\" data-linked=\"Seres Therapeutics&#39; lead product candidate shows positive effect in mid-stage C. diff study; shares ahead 10% premarket\" data-tweet=\"$MCRB - Seres Therapeutics&#39; lead product candidate shows positive effect in mid-stage C. diff study; shares ahead 10% premarket https://seekingalpha.com/news/3239099-seres-therapeutics-lead-product-candidate-shows-positive-effect-in-mid-stage-c-diff-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3239099-seres-therapeutics-lead-product-candidate-shows-positive-effect-in-mid-stage-c-diff-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239094\" data-ts=\"1485872157\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239094-premarket-gainers-losers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers / Losers as of 9:10 am</a></h4><ul> <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='green'>+45%</font>. <a href='https://seekingalpha.com/symbol/AEZS' title='AEterna Zentaris, Inc.'>AEZS</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/RGSE' title='RGS Energy, Inc.'>RGSE</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/MNTA' title='Momenta Pharmaceuticals, Inc.'>MNTA</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/SINO' title='Sino-Global Shipping America, Ltd.'>SINO</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/XGTI' title='xG Technology, Inc.'>XGTI</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/AUDC' title='AudioCodes Ltd.'>AUDC</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/CLRB' title='Cellectar Biosciences, Inc.'>CLRB</a> <font color='green'>+5%</font>.</li> <li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DMTX' title='Dimension Therapeutics'>DMTX</a> <font color='red'>-32%</font>. <a href='https://seekingalpha.com/symbol/UAA' title='Under Armour, Inc.'>UAA</a> <font color='red'>-27%</font>. <a href='https://seekingalpha.com/symbol/UA' title='Under Armour, Inc. Class C'>UA</a> <font color='red'>-25%</font>. <a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited &#40;New&#41;'>SDRL</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/ESES' title='Eco-Stim Energy Solutions, Inc.'>ESES</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/EYEG' title='EyeGate Pharmaceuticals'>EYEG</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SMLP' title='Summit Midstream Partners'>SMLP</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SDLP' title='Seadrill Partners, LLC'>SDLP</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/HOG' title='Harley-Davidson, Inc.'>HOG</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/IDTI' title='Integrated Device Technology, Inc.'>IDTI</a> <font color='red'>-6%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3239094\" data-linked=\"Premarket Gainers / Losers as of 9:10 am\" data-tweet=\"$DRYS $AEZS $RGSE - Premarket Gainers / Losers as of 9:10 am https://seekingalpha.com/news/3239094-premarket-gainers-losers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3239094-premarket-gainers-losers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239093\" data-ts=\"1485872142\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TPR\" target=\"_blank\">TPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239093-coach-tops-north-america-comparable-sales-expectations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coach tops North America comparable sales expectations</a></h4><ul> <li>Coach (COH) reports North American comparable sales increased 3.0% in <a href=\"https://seekingalpha.com/pr/16727629-coach-inc-reports-fiscal-2017-second-quarter-results-drives-double-digit-earnings-growth\" target=\"_blank\">FQ2</a> to top the consensus estimate of analysts calling for a 2.4% gain.</li> <li>International Coach brand sales rose 3% to $448M (+1% on a constant currency basis). Strong results from Macau contributed.</li> <li>Gross margin during the quarter was up 140 bps to 68.6% of sales. Operating margin fell 10 bps to 22.3% of sales.</li> <li>Coach expects revenue to increase at a low single-digit pace, inclusive of a negative impact from F/X.</li> <li>COH <font color='green'>+0.61%</font> premarket to $36.20.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3239093\" data-linked=\"Coach tops North America comparable sales expectations\" data-tweet=\"$TPR - Coach tops North America comparable sales expectations https://seekingalpha.com/news/3239093-coach-tops-north-america-comparable-sales-expectations?source=tweet\" data-url=\"https://seekingalpha.com/news/3239093-coach-tops-north-america-comparable-sales-expectations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239079\" data-ts=\"1485871043\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GTE\" target=\"_blank\">GTE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239079-gran-tierra-energy-to-make-normal-course-issuer-bid\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gran Tierra Energy to make normal course issuer bid</a></h4><ul>     <li>Gran Tierra Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/GTE' title='Gran Tierra Energy, Inc'>GTE</a>)&nbsp;<font color='green'>+3.7%</font> premarket on news that it plans to make a <a href=\"https://seekingalpha.com/pr/16727384-gran-tierra-energy-inc-announces-notice-intention-make-normal-course-issuer-bid\" target=\"_blank\">normal course issuer bid</a> to purchase for cancellation up to ~5% of its issued and outstanding common shares.</li>     <li>GTE says its shares at times have traded at a price that does not adequately reflect their value in relation to the company's current operations, growth prospects and financial position.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3239079\" data-linked=\"Gran Tierra Energy to make normal course issuer bid\" data-tweet=\"$GTE - Gran Tierra Energy to make normal course issuer bid https://seekingalpha.com/news/3239079-gran-tierra-energy-to-make-normal-course-issuer-bid?source=tweet\" data-url=\"https://seekingalpha.com/news/3239079-gran-tierra-energy-to-make-normal-course-issuer-bid\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239075\" data-ts=\"1485870818\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DMTX\" target=\"_blank\">DMTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239075-dimension-therapeutics-gene-therapy-candidate-for-hemophilia-b-shows-treatment-benefit-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dimension Therapeutics&#39; gene therapy candidate for hemophilia B shows treatment benefit in early-stage study but side effects troubling; shares down 33% premarket</a></h4><ul><li>Thinly traded micro cap Dimension Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/DMTX' title='Dimension Therapeutics'>DMTX</a>) is off&nbsp;<font color='red'>33%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16727817-dimension-announces-interim-topline-results-ongoing-phase-1-2-clinical-program-dtx101\" target=\"_blank\">announcement </a>of interim results from a Phase 1/2 clinical trial assessing gene therapy candidate, Orphan Drug-tagged DTX101, in adult patients with hemophilia B, an inherited bleeding disorder caused by a deficiency in blood clotting Factor IX &#40;FIX&#41;. DTX101 is designed to deliver stable expression of FIX.</li><li>Data from the first two dose cohorts showed a positive treatment effect over follow-up periods ranging from six to 52 weeks. Patients in the second cohort (n=3) showed peak FIX expression of 13%, 20% and 12% at weeks 4, 8 and 8, respectively. FIX activity was 5% and 8% in two patients at 12 weeks follow-up and 7% for the third patient at 7 weeks. The low-dose cohort (n=3) also experienced a positive, albeit slightly lower, treatment benefit.</li><li>Treatment with DTX101 stressed the liver in five of the six participants, however, as measured by elevations in an enzyme called alanine aminotransferase &#40;ALT&#41;. One patient in the second cohort experience a grade 4 (disabling or life-threatening) adverse event due to elevated ALT. All elevations were clinically asymptomatic with no elevations in certain other liver damage biomarkers. Patients received a tapering course of corticosteroids which returned ALT levels to the normal range in all but one patient.</li></ul><div class=\"tiny-share-widget\" data-id=\"3239075\" data-linked=\"Dimension Therapeutics&#39; gene therapy candidate for hemophilia B shows treatment benefit in early-stage study but side effects troubling; shares down 33% premarket\" data-tweet=\"$DMTX - Dimension Therapeutics&#39; gene therapy candidate for hemophilia B shows treatment benefit in early-stage study but side effects troubling; shares down 33% premarket https://seekingalpha.com/news/3239075-dimension-therapeutics-gene-therapy-candidate-for-hemophilia-b-shows-treatment-benefit-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3239075-dimension-therapeutics-gene-therapy-candidate-for-hemophilia-b-shows-treatment-benefit-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239074\" data-ts=\"1485870696\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIT\" target=\"_blank\">FIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239074-fitbit-downgraded-to-sell-citi-target-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fitbit downgraded to Sell at Citi, target $5</a></h4><ul><li>From Neutral, <a href=\"http://www.streetinsider.com/Downgrades/Citi+Downgrades+Fitbit+%28FIT%29+to+Sell/12477328.html\" target=\"_blank\">analyst Stanley Kovler</a> notes Fitbit's <a href=\"https://seekingalpha.com/news/3238697-fitbit-minus-11_8-percent-q4-2016-preliminary-results-fy-2017-outlook-significantly\" target=\"_blank\">negative Q4 2016 preliminary reporting and below-consensus FY 2017 forecast</a>, and spotlights lacking management visibility into the company's distribution network, confirmation of impact of market saturation, restructuring initiatives considered only a start, and prolonged promotional initiatives which could result in long-term expectations for lower fitness tracker pricing.</li><li>Fitbit (NYSE:<a href='https://seekingalpha.com/symbol/FIT' title='Fitbit, Inc.'>FIT</a>) $5.99,&nbsp;<font color='red'>-1.16%</font>&nbsp;pre-market.</li><li>Related (January 30, 2016):&nbsp;<a href=\"https://seekingalpha.com/news/3238780-fitbit-target-lowered-6_50-mizuho-securities\" target=\"_blank\">Fitbit target lowered to $6.50 at Mizuho Securities</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3239074\" data-linked=\"Fitbit downgraded to Sell at Citi, target $5\" data-tweet=\"$FIT - Fitbit downgraded to Sell at Citi, target $5 https://seekingalpha.com/news/3239074-fitbit-downgraded-to-sell-citi-target-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3239074-fitbit-downgraded-to-sell-citi-target-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239063\" data-ts=\"1485869578\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDX\" target=\"_blank\">FDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239063-fedexminus-1_7-after-ups-disappointment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FedEx -1.7% after UPS disappointment</a></h4><ul><li>An earnings miss and soft guidance has UPS<font color='red'> lower by 4.9%</font>&nbsp;premarket. Down alongside is FedEx (NYSE:<a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a>),&nbsp;<font color='red'>off 1.7%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3239038-weak-guidance-earnings-miss-sends-ups-lower\" target=\"_blank\">Weak guidance and earnings miss sends UPS lower</a> (Jan. 31)</li></ul><div class=\"tiny-share-widget\" data-id=\"3239063\" data-linked=\"FedEx -1.7% after UPS disappointment\" data-tweet=\"$FDX - FedEx -1.7% after UPS disappointment https://seekingalpha.com/news/3239063-fedexminus-1_7-after-ups-disappointment?source=tweet\" data-url=\"https://seekingalpha.com/news/3239063-fedexminus-1_7-after-ups-disappointment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239062\" data-ts=\"1485869540\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HCA\" target=\"_blank\">HCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239062-hca-holdings-beats-0_10-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HCA Holdings beats by $0.10, misses on revenue</a></h4><ul><li>HCA Holdings (NYSE:<a href='https://seekingalpha.com/symbol/HCA' title='HCA Holdings, Inc.'>HCA</a>): Q4 EPS of $1.89 <font color='green'>beats by $0.10</font>.</li><li>Revenue of $10.64B (+3.8% Y/Y) <font color='red'>misses by $30M</font>.</li><li>Shares <font color='green'>+3.42%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/16727978-hca-reports-fourth-quarter-2016-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3239062\" data-linked=\"HCA Holdings beats by $0.10, misses on revenue\" data-tweet=\"$HCA - HCA Holdings beats by $0.10, misses on revenue https://seekingalpha.com/news/3239062-hca-holdings-beats-0_10-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3239062-hca-holdings-beats-0_10-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239055\" data-ts=\"1485869184\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BWLD\" target=\"_blank\">BWLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239055-clsa-sees-downward-trip-for-buffalo-wild-wings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CLSA sees downward trip for Buffalo Wild Wings</a></h4><ul> <li>Shares of Buffalo Wild Wings (<a href='https://seekingalpha.com/symbol/BWLD' title='Buffalo Wild Wings, Inc.'>BWLD</a>) head lower after CLSA <a href=\"https://www.marketbeat.com/stocks/NASDAQ/bwld\" target=\"_blank\">slaps</a> a Sell rating on the restaurant stock.</li> <li>The investment firm raises concerns on comparable sales trends for Buffalo Wild Wings and broader industry concerns such as U.S. casual dining oversaturation.</li> <li>CLSA lowers its price target to $141 from $146.</li> <li>BWLD <font color='red'>-0.67%</font> premarket to $155.40.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3239055\" data-linked=\"CLSA sees downward trip for Buffalo Wild Wings\" data-tweet=\"$BWLD - CLSA sees downward trip for Buffalo Wild Wings https://seekingalpha.com/news/3239055-clsa-sees-downward-trip-for-buffalo-wild-wings?source=tweet\" data-url=\"https://seekingalpha.com/news/3239055-clsa-sees-downward-trip-for-buffalo-wild-wings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3239045\" data-ts=\"1485868621\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MA\" target=\"_blank\">MA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3239045-mastercard-lower-after-revenue-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MasterCard lower after revenue miss</a></h4><ul> <li>MasterCard (NYSE:<a href='https://seekingalpha.com/symbol/MA' title='Mastercard, Inc.'>MA</a>) reports revenue increased 10% in <a href=\"https://seekingalpha.com/pr/16727857-mastercard-incorporated-reports-fourth-quarter-full-year-2016-financial-results\" target=\"_blank\">Q4</a> on a currency-neutral basis.</li> <li>Switched transactions were up 17% to 15.2B during the quarter.</li> <li>Gross dollar volume increased 9% to $1.2T (adjusted for EU regulatory changes).</li> <li>Cross-border volume was up 13% Y/Y.</li> <li>MasterCard's effective tax rate in Q4 was 28.7% vs. 13.1% a year ago when discrete benefits factored in.</li> <li>Operating margin was 49.8%, adjusting for special items.</li> <li>MA <font color='red'>-2.77%</font> premarket to $106.27.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3239028-mastercard-beats-0_01-misses-revenue\" target=\"_blank\">MasterCard beats by $0.01, misses on revenue</a> (Jan. 31)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3239045\" data-linked=\"MasterCard lower after revenue miss\" data-tweet=\"$MA - MasterCard lower after revenue miss https://seekingalpha.com/news/3239045-mastercard-lower-after-revenue-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3239045-mastercard-lower-after-revenue-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}